# agentsite-static-version=b826138e-f9d0-4b6a-b9af-387e387352d5
# iqvia.com
> AI-optimized mirror of iqvia.com containing 250 pages totalling 160,595 words of clean markdown content, structured data, and semantic HTML. Original source: https://iqvia.com. Last updated: 2026-09-24T16:38:23.072Z.
Each page is available as HTML (with JSON-LD structured data) and Markdown (text-only, ideal for LLMs and RAG).
## Homepage
- [Transforming Life Sciences with Data, Technology & Human Science | IQVIA](/content/site-root.html): IQVIA empowers life sciences organizations to accelerate innovation, improve patient outcomes, and bring treatments to market faster through advanced analytics and technology. (868 words)
## Articles & Blog Posts
- [locations/argentina/index.html](/content/locations/argentina/index.html) (225 words)
- [IQVIA MedTech Quality Assurance | IQVIA](/content/sub-brands/medtech/quality-assurance/index.html): MedTech Compliance & Quality Services (1,450 words)
- [RIMSmart | IQVIA](/content/form-pages/rimsmart/index.html): RIMSmart (453 words)
- [Vigilance | IQVIA](/content/form-pages/vigilance/index.html): Vigilance (147 words)
- [it-it/locations/argentina/index.html](/content/it-it/locations/argentina/index.html) (202 words)
- [Medical Device Reimbursement Consulting & Strategy | IQVIA](/content/sub-brands/medtech/reimbursement/index.html): Navigate coverage and payment pathways with IQVIA MedTech’s medical device reimbursement experts. From strategy to execution, we help drive market access.
(939 words)
- [MedTech Device Expertise | IQVIA](/content/sub-brands/medtech/device-expertise/index.html): MedTech consulting and CRO services for IVD, biologics, combination products, and digital health—helping innovators move from concept to commercialization. (778 words)
- [Vigilance | IQVIA](/content/form-pages/vigilanceintake/index.html): VigilanceIntake (455 words)
- [MedTech Regulatory Consulting and Services | IQVIA](/content/sub-brands/medtech/regulatory-services/index.html): Navigate medical device regulations with IQVIA MedTech regulatory consulting. Ensure compliance, reduce risk, and accelerate approvals worldwide. (1,031 words)
- [Medical Device Therapeutic Areas | IQVIA](/content/sub-brands/medtech/therapeutic-areas/index.html): Explore IQVIA MedTech’s therapeutic expertise across key medical device areas. Deep clinical knowledge supporting innovation, trials and commercialization. (541 words)
- [IQVIA AI Subscription | IQVIA](/content/form-pages/iqviaaisubscription/index.html): IQVIAAISubscription (385 words)
- [IQVIA Safe Entry | IQVIA](/content/form-pages/safeentry/index.html): SafeEntry (440 words)
- [MedTech Clinical Trial Services | IQVIA](/content/sub-brands/medtech/clinical-research/index.html): Advance your medical device with IQVIA MedTech clinical research. Global trials, regulatory expertise, and proven success in bringing innovations to market. (841 words)
- [BookMeetingCPHi | IQVIA](/content/form-pages/bookmeetingcphi/index.html): BookMeetingCPHi (428 words)
- [Contact Us | IQVIA](/content/form-pages/regulatory/index.html): ContactUs (378 words)
- [IQVIATechIQSubscription | IQVIA](/content/form-pages/iqviatechiqsubscription/index.html): IQVIATechIQSubscription (385 words)
- [Medical Device, Diagnostics and Digital Health Insights | IQVIA](/content/sub-brands/medtech/insights/index.html): Insights (169 words)
- [MedTech Market Access and Commercialization | IQVIA](/content/sub-brands/medtech/commercialization/index.html): Maximize market success with IQVIA MedTech commercialization. From strategy to reimbursement, we drive medical device adoption and revenue growth. (535 words)
- [Institute Subscription | IQVIA](/content/form-pages/institutesubscription/index.html): InstituteSubscription (132 words)
- [Blogs | IQVIA](/content/sub-brands/medtech/blogs/index.html): Blogs (199 words)
- [SuppliersData | IQVIA](/content/form-pages/suppliersdata/index.html): SuppliersData (232 words)
- [Human Data Science Research Collaborative in the Era of COVID 19 - Application Form | IQVIA](/content/form-pages/hdsapplication/index.html): HDSapplication (636 words)
- [IQVIAAI | IQVIA](/content/form-pages/aiplatform/index.html): AIPlatform (384 words)
- [U.S. Launch Quarterly Subscription | IQVIA](/content/form-pages/usinsights/index.html): USInsights (103 words)
- [One Home for Sites: Become a Partner | IQVIA](/content/form-pages/onehometechpartner/index.html): Form page for One Home Technologies Partner (157 words)
- [U.S. Progress Point Subscription | IQVIA](/content/form-pages/usprogresspoint/index.html): USProgressPoint (47 words)
- [Life Sciences Customer Experience Platform Provider Compendium 2023 | IQVIA](/content/analyst-reports/report/life-sciences-customer-experience-platform-provider-compendium-2023.html): Life Sciences Customer Experience Platform Provider Compendium 2023 (47 words)
- [IQVIA ranked #1 in Everest Group's Top 50™ Pharmaceutical Technology Providers 2026 | IQVIA](/content/analyst-reports/report/iqvia-ranked-1-in-everest-groups-top-50-pharmaceutical-technology-providers-2026.html): Explore why IQVIA ranked #1 in Everest Group’s Top 50 Pharmaceutical Technology Providers 2026 report and how leading pharmaceutical technology providers are shaping the future of life sciences through AI, cloud modernization, ecosystem partnerships, Systems of Execution, data automation and intelligent execution across the pharmaceutical value chain. (187 words)
- [IDC Perspective: How Data Interoperability and Federated Learning Are Fueling a Precision Medicine Strategy and Transforming Drug Repurposing | IQVIA](/content/analyst-reports/report/idc-perspective-how-data-interoperability-and-federated-learning-are-fueling.html): This IDC Perspective discusses the increasing significance of federated learning (FL) models in promoting collaboration within the life sciences industry. It highlights examples of FL model implementation and addresses the complexities and challenges associated with its adoption. The report emphasizes FL's potential to accelerate various aspects of drug development, including discovery, repurposing, and repositioning, while urging the life sciences industry to harness its capabilities and implement necessary safeguards to ensure its successful utilization. (97 words)
- [NVIDIA's Groundbreaking Partnerships to Scale Innovation and Revolutionize Genomics, Drug Discovery, and Healthcare | IQVIA](/content/analyst-reports/report/nvidias-groundbreaking-partnerships-to-scale-innovation-revolutionize-genomics-drug-discovery.html): IDC NVIDIA's Groundbreaking Partnerships to Scale Innovation and Revolutionize Genomics, Drug Discovery, and Healthcare January 21, 2025 (101 words)
- [IDC MarketScape: Worldwide Life Science Sales and Marketing IT Outsourcing Services 2022 Vendor Assessment | IQVIA](/content/analyst-reports/report/idc-marketscape-worldwide-life-science-sales-and-marketing-it-outsourcing-services-2022-vendor.html): This IDC study provides an assessment of 11 vendors offering IT outsourcing solutions for sales and marketing processes in the life science industry. Highly experienced vendors are offering increasingly sophisticated ITO models for processes leveraging these technologies while allowing these companies to focus on their core competencies. Life science companies will continue to see improved outcomes, growth, and productivity as they free their organizations to focus on core innovation and business cases, using these offerings to improve outcomes for doctors and patients alike.
(105 words)
- [IDC MarketScape: Worldwide Life Science R&D Pharmacovigilance Solutions 2022 Vendor Assessment | IQVIA](/content/analyst-reports/report/idc-marketscape-worldwide-life-science-rd-pharmacovigilance-solutions-2022-vendor-assessment.html): IQVIA was recently recognized as a Leader in "IDC MarketScape: Worldwide Life Science R&D Pharmacovigilance Solutions 2022 Vendor Assessment", December 2022, IDC # US48061622. The report emphasizes IQVIA's deep proven pharmacovigilance and operational expertise, insight into the industry landscape, including regulations across geographies, and breadth of services. (149 words)
- [Top Technology Trends for Life Science CIOs for 2025 | IQVIA](/content/analyst-reports/report/top-technology-trends-for-life-science-cios-for-2025.html): Gartner Analyst Report Top Technology Trends for Life Science CIOs for 2025 (74 words)
- [Life Sciences Clinical Data and Analytics Platforms – Provider Compendium 2025 | IQVIA](/content/analyst-reports/report/life-sciences-clinical-data-and-analytics-platforms-provider-compendium-2025.html): Analyst Report Everest Group Life Sciences Clinical Data and Analytics Platforms – Provider Compendium 2025 February 28, 2025 (33 words)
- [Everest Group Life Sciences Next-generation Customer Engagement Platforms PEAK Matrix® Assessment 2023 | IQVIA](/content/analyst-reports/report/life-sciences-operations-peak-matrix-assessment-2023.html): Life Sciences Operations PEAK Matrix Assessment 2023 (37 words)
- [MedTech Operations Provider Compendium 2024 | IQVIA](/content/analyst-reports/report/medtech-operations-provider-compendium-2024/index.html): Everest Group’s MedTech Operations – Service Provider Compendium 2024 provides comprehensive and fact-based snapshots of 15 MedTech operations service providers. Each provider profile offers a comprehensive picture of its company overview, key leaders, scale of operations, recent developments and investments, partnerships, technology solutions and capabilities, delivery locations, scope of services, and portfolio mix. The compendium will enable providers to benchmark themselves against their competitors, while buyers will be able to assess the providers based on the desired set of capabilities. (90 words)
- [IDC Link: Building One Home for Sites — How IQVIA Aims to Transform the Site Experience | IQVIA](/content/analyst-reports/report/idc-building-one-home-for-sites/index.html): One Home for Sites is well positioned to really transform the site experience, driving faster and improved patient outcomes and simplifying the workload for technology vendors, sponsors and other CROs. (155 words)
- [Life Sciences Sales and Marketing Operations Provider Compendium 2023 | IQVIA](/content/analyst-reports/report/life-sciences-sales-and-marketing-operations-provider-compendium-2023.html): Life Sciences Sales and Marketing Operations Provider Compendium 2023 (31 words)
- [Join to hear about the latest insights from EMEA Thought Leadership | IQVIA](/content/form-pages/emeasubscription/index.html): EMEASubscription (47 words)
- [Pharmacovigilance Operations PEAK Matrix Assessment 2025 | IQVIA](/content/analyst-reports/report/pharmacovigilance-operations-peak-matrix-assessment-2025.html): External link to Everest Group Pharmacovigilance Operations PEAK Matrix Assessment 2025 analyst report (85 words)
- [Hype Cycle for Life Science Clinical Development, 2023 | IQVIA](/content/analyst-reports/report/hype-cycle-for-life-science-clinical-development-2023.html): Amid highly disruptive advances in artificial intelligence this year, life science companies must continue to navigate the strong current of inflationary market forces. CIOs must make difficult choices, selecting innovations that enable operational excellence and robust returns on investment.
Report Attribution
Please use the following required formatting: Gartner, [Report Title], [Authors], [Publication Date]. You may also refer to the Content Compliance Policy to capture the required formatting.
Trademark Disclaimer (Gartner® Hype Cycle™)
GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally, and HYPE CYCLE is a registered trademark of Gartner, Inc. and/or its affiliates and are used herein with permission. All rights reserved.
Objectivity Disclaimer
Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
(204 words)
- [Hype Cycle for Legal and Compliance Technologies, 2023 | IQVIA](/content/analyst-reports/report/hype-cycle-for-legal-and-compliance-technologies-2023.html): Tech innovations grow increasingly important for corporate legal and compliance leaders facing significant workload demands and looming economic and regulatory headwinds. Leaders must close foundational tech gaps and carefully pursue innovation to deliver outcomes effectively for their business.
Report Attribution
Please use the following required formatting: Gartner, [Report Title], [Authors], [Publication Date]. You may also refer to the Content Compliance Policy to capture the required formatting.
Trademark Disclaimer (Gartner® Hype Cycle™)
GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally, and HYPE CYCLE is a registered trademark of Gartner, Inc. and/or its affiliates and are used herein with permission. All rights reserved.
Objectivity Disclaimer
Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
(202 words)
- [IDC Perspective: How Technology Is Driving Diversity and Equity in Clinical Trials | IQVIA](/content/analyst-reports/report/idc-perspective-how-technology-is-driving-diversity-and-equity-in-clinical-trials.html): This IDC Perspective highlights the importance of diversity and equity in clinical trials, acknowledging the deep-rooted disparities in healthcare. It discusses strategies employed by pharmaceutical companies to address these challenges, emphasizes the role of evolving technology, considers regulatory policies, and provides guidance on implementing diversity strategies, emphasizing the need for a sustained and collaborative effort. (72 words)
- [Hype Cycle for Life Science Commercial Operations, 2023 | IQVIA](/content/analyst-reports/report/hype-cycle-for-life-science-commercial-operations-2023.html): Life science organizations strive to balance innovation and operational value delivery. This Hype Cycle provides CIOs with strategic input by tracking maturity levels and adoption rates of key technologies to guide commercialization planning and investments.
Report Attribution
Please use the following required formatting: Gartner, [Report Title], [Authors], [Publication Date]. You may also refer to the Content Compliance Policy to capture the required formatting.
Trademark Disclaimer (Gartner® Hype Cycle™)
GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally, and HYPE CYCLE is a registered trademark of Gartner, Inc. and/or its affiliates and are used herein with permission. All rights reserved.
Objectivity Disclaimer
Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
(196 words)
- [Hype Cycle for Life Science Manufacturing, Quality and Supply Chain, 2023 | IQVIA](/content/analyst-reports/report/hype-cycle-for-life-science-manufacturing-quality-and-supply-chain-2023.html): Life science manufacturers must continuously innovate and streamline processes to produce high-quality, regulated products. CIOs can use this Hype Cycle to identify opportunities and assess risks for technologies that optimize and facilitate manufacturing, quality and supply chain operations.
Report Attribution
Please use the following required formatting: Gartner, [Report Title], [Authors], [Publication Date]. You may also refer to the Content Compliance Policy to capture the required formatting.
Trademark Disclaimer (Gartner® Hype Cycle™)
GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally, and HYPE CYCLE is a registered trademark of Gartner, Inc. and/or its affiliates and are used herein with permission. All rights reserved.
Objectivity Disclaimer
Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
(205 words)
- [IDC MarketScape: Worldwide Life Sciences Sales and Marketing Strategic Consulting Services 2023 Vendor Assessment | IQVIA](/content/analyst-reports/report/idc-marketscape-worldwide-life-sciences-sales-and-marketing-strategic-consulting-services-2023.html): This IDC study provides an assessment of 12 vendors offering strategic consulting solutions for sales and marketing processes in the life science industry. Tools such as artificial intelligence (AI), advanced analytics, and orchestration of multiple tasks and roles utilizing data from multiple sources are accelerating change in 2023 and beyond and helping expand the scope of business processes suitable for outsourcing to qualified vendors. (87 words)
- [IDC MarketScape: Worldwide Life Science R&D Decentralized Clinical Trial Consulting Services 2022 Vendor Assessment | IQVIA](/content/analyst-reports/report/idc-marketscape-worldwide-life-science-rd-decentralized-clinical-trial-consulting-services-2022.html): There is a need to build a playbook to drive the enterprisewide implementation of the DCT model, automatically optimizing the technology mix based on the study type. With a specific focus on strategic consulting in the life science R&D DCT space, this document is a qualitative and quantitative assessment based on criteria that should be important to life science companies when considering the selection of a strategic DCT consulting partner to help provide guidance for strategic, operational, and tactical transformation issues within the DCT space. (104 words)
- [IDC MarketScape: Worldwide Life Science R&D Decentralized Clinical Trial Technology Solutions 2022 Vendor Assessment | IQVIA](/content/analyst-reports/report/idc-marketscape-worldwide-life-science-rd-decentralized-clinical-trial-technology-solutions-2022.html): With a specific focus on strategic consulting in the life science R&D DCT space, this document is a qualitative and quantitative assessment based on criteria that should be important to life science companies when considering the selection of a strategic DCT consulting partner to help provide guidance for strategic, operational, and tactical transformation issues within the DCT space. (77 words)
- [Hype Cycle for Life Science Discovery Research, 2023 | IQVIA](/content/analyst-reports/report/hype-cycle-for-life-science-discovery-research-2023.html): Life science companies continue to build new capabilities in digital research and early stage drug discovery capabilities. CIOs can use this Hype Cycle to identify innovative technologies reshaping their industry and to prioritize their investments accordingly.
Report Attribution
Please use the following required formatting: Gartner, [Report Title], [Authors], [Publication Date]. You may also refer to the Content Compliance Policy to capture the required formatting.
Trademark Disclaimer (Gartner® Hype Cycle™)
GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally, and HYPE CYCLE is a registered trademark of Gartner, Inc. and/or its affiliates and are used herein with permission. All rights reserved.
Objectivity Disclaimer
Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
(198 words)
- [Hype Cycle for Healthcare Data, Analytics and AI, 2023 | IQVIA](/content/analyst-reports/report/hype-cycle-for-healthcare-data-analytics-and-ai-2023.html): This Hype Cycle tracks the emerging technologies that will have the greatest impact on data, analytics and AI initiatives in the payer, provider and life science sectors. CIOs can use this critical insight to guide their strategic planning decisions.
Report Attribution
Please use the following required formatting: Gartner, [Report Title], [Authors], [Publication Date]. You may also refer to the Content Compliance Policy to capture the required formatting.
Trademark Disclaimer (Gartner® Hype Cycle™)
GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally, and HYPE CYCLE is a registered trademark of Gartner, Inc. and/or its affiliates and are used herein with permission. All rights reserved.
Objectivity Disclaimer
Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
(202 words)
- [IDC: How Predictive Analytics Technologies Are Reshaping the Life Science Industry | IQVIA](/content/analyst-reports/report/idc-how-predictive-analytics-technologies-are-reshaping-the-life-science-industry.html): This IDC Perspective emphasizes the significance of predictive analytics technologies in driving innovation and informed decision-making in the life science industry. It discusses key drivers, challenges, and complexities associated with implementing predictive analytics and highlights the evolving market landscape. Life science organizations are transitioning from being data-hungry to data-driven, positioning themselves as intelligent enterprises focused on learning, synthesizing information, and applying insights at scale for a competitive advantage. (84 words)
- [Forrester: CRM Goes Vertical In The Age Of The Customer | IQVIA](/content/analyst-reports/report/forrester-crm-goes-vertical-in-the-age-of-the-customer.html): Forrester CRM Goes Vertical In The Age Of The Customer (25 words)
- [Hype Cycle for Digital Care Delivery Including Virtual Care, 2023 | IQVIA](/content/analyst-reports/report/hype-cycle-for-digital-care-delivery-including-virtual-care-2023.html): This Hype Cycle identifies and tracks digital innovations and market solutions for optimizing and transforming the way in which healthcare providers deliver clinical care. CIOs can use this research to assess the value and impact of new technologies and solutions shaping investment strategies.
Report Attribution
Please use the following required formatting: Gartner, [Report Title], [Authors], [Publication Date]. You may also refer to the Content Compliance Policy to capture the required formatting.
Trademark Disclaimer (Gartner® Hype Cycle™)
GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally, and HYPE CYCLE is a registered trademark of Gartner, Inc. and/or its affiliates and are used herein with permission. All rights reserved.
Objectivity Disclaimer
Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
(216 words)
- [Quick Answer: Why is There So Much Hype About Data Monetization in Healthcare? | IQVIA](/content/analyst-reports/report/gartner-quick-answer-why-is-there-so-much-hype-about-data-monetization-in-healthcare.html): Healthcare data and analytics leaders are seeing vendor solicitations and questions from internal executive peers about buying and selling healthcare data. This research describes key dynamics that are amplifying hype about data monetization — helping CIOs separate signal from noise.
Report Attribution
Please use the following required formatting: Gartner, [Report Title], [Authors], [Publication Date]. You may also refer to the Content Compliance Policy to capture the required formatting.
Trademark Disclaimer (Gartner®)
GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and is used herein with permission. All rights reserved.
Objectivity Disclaimer
Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
(191 words)
- [Market Guide for Life Science Regulatory Information Management Solutions | IQVIA](/content/analyst-reports/report/gartner-market-guide-for-life-science-regulatory-information-management-solutions.html): Regulatory information management vendors continue to enhance offerings, but legacy business processes and integration points hamper progress. Life science CIOs should use this research to select the best solution supporting a holistic regulatory approach.
Report Attribution
Please use the following required formatting: Gartner, [Report Title], [Authors], [Publication Date]. You may also refer to the Content Compliance Policy to capture the required formatting.
Trademark Disclaimer (Gartner®)
GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and is used herein with permission. All rights reserved.
Objectivity Disclaimer
Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
(186 words)
- [Voice of the Customer for Data Masking | IQVIA](/content/analyst-reports/report/gartner-voice-of-the-customer-for-data-masking/index.html): Data masking enables organizations to transform sensitive data elements to ensure the original values are not identifiable when used in application testing environments. Security and risk management leaders can learn from ratings and reviews by their peers shared on Gartner Peer Insights.
Report Attribution
Please use the following required formatting: Gartner, [Report Title], [Authors], [Publication Date]. You may also refer to the Content Compliance Policy to capture the required formatting.
Trademark Disclaimer (Gartner®)
GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and is used herein with permission. All rights reserved.
Objectivity Disclaimer
Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
(188 words)
- [Hype Cycle for Healthcare Providers, 2023 | IQVIA](/content/analyst-reports/report/hype-cycle-for-healthcare-providers-2023/index.html): This Hype Cycle tracks the benefits and maturity levels of digital innovations, market solutions and approaches for healthcare providers. It helps CIOs communicate with stakeholders on the future direction of IT and supports decision making to identify, understand and prioritize investments.
Report Attribution
Please use the following required formatting: Gartner, [Report Title], [Authors], [Publication Date]. You may also refer to the Content Compliance Policy to capture the required formatting.
Trademark Disclaimer (Gartner® Hype Cycle™)
GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally, and HYPE CYCLE is a registered trademark of Gartner, Inc. and/or its affiliates and are used herein with permission. All rights reserved.
Objectivity Disclaimer
Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
(200 words)
- [Healthcare's Digital Backbone: A Deep Dive into Data Management Platforms | IQVIA](/content/analyst-reports/report/healthcares-digital-backbone-a-deep-dive-into-data-management-platforms.html): Analyst Report Everest Group Healthcare's Digital Backbone: A Deep Dive into Data Management Platforms February 26, 2025 (32 words)
- [Life Science CIOs Reduce Runaway Costs With Innovative Safety Vigilance Technology | IQVIA](/content/analyst-reports/report/gartner-life-science-cios-reduce-runaway-costs-with-innovative-safety-vigilance-technology.html): Life science companies are grappling with a steady increase in safety events, and the safety vigilance technology landscape is being disrupted by new AI, automation and cloud approaches. CIOs can use these advances to optimize their safety platforms and lower clinical development costs.
Report Attribution
Please use the following required formatting: Gartner, [Report Title], [Authors], [Publication Date]. You may also refer to the Content Compliance Policy to capture the required formatting.
Trademark Disclaimer (Gartner®)
GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and is used herein with permission. All rights reserved.
Objectivity Disclaimer
Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
(196 words)
- [Quick Answer: How Should Life Science CIOs Position Their Data for Success With IDMP? | IQVIA](/content/analyst-reports/report/gartner-quick-answer-how-should-life-science-cios-position-their-data-for-success-with-idmp.html): The European Medicine Agency continues taking cautious steps toward implementing Identification of Medicinal Products by introducing new updates in its proposed IDMP plan. Life science CIOs can use this research to stay agile in the face of change, speeding compliance with EMA regulations.
Report Attribution
Please use the following required formatting: Gartner, [Report Title], [Authors], [Publication Date]. You may also refer to the Content Compliance Policy to capture the required formatting.
Trademark Disclaimer (Gartner®)
GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and is used herein with permission. All rights reserved.
Objectivity Disclaimer
Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
(198 words)
- [Innovation Insight for Aggregate Spend and Global Transparency Reporting | IQVIA](/content/analyst-reports/report/gartner-innovation-insight-for-aggregate-spend-and-global-transparency-reporting.html): Global transparency reporting platforms support the tracking, monitoring and reporting of transfer of value required to comply with regional transparency regulations. Life science CIOs should use this research to modernize their capabilities for reducing reputational risks and improving compliance.
Report Attribution
Please use the following required formatting: Gartner, [Report Title], [Authors], [Publication Date]. You may also refer to the Content Compliance Policy to capture the required formatting.
Trademark Disclaimer (Gartner®)
GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and is used herein with permission. All rights reserved.
Objectivity Disclaimer
Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
(186 words)
- [Gartner Hype Cycle for Real Time Health System Technologies, 2026 | IQVIA](/content/analyst-reports/report/gartner-hype-cycle-for-real-time-health-system-technologies-2026.html): Gartner Hype Cycle for Real Time Health System Technologies May 19, 2026. (50 words)
- [Gartner Market Guide for CRM in Life Sciences | IQVIA](/content/analyst-reports/report/gartner-market-guide-for-crm-in-life-sciences/index.html): External link to Gartner landing page for Market Guide for CRM in Life Sciences report (15 words)
- [Gartner Hype Cycle for Life Science Manufacturing | IQVIA](/content/analyst-reports/report/gartner-hype-cycle-for-life-science-manufacturing/index.html): Gartner Hype Cycle for Life Science Manufacturing June 9, 2026
(14 words)
- [How Life Science CIOs Can Build a Data-Driven Enterprise Foundation With Commercial MDM | IQVIA](/content/analyst-reports/report/gartner-how-life-science-cios-can-build-a-data-driven-enterprise-foundation-with-commercial-mdm.html): Life science organizations have lofty ambitions to leverage data and improve strategic decision-making capabilities through analytics. CIOs must invest in and scale the use of MDM to generate value from information.
Report Attribution
Please use the following required formatting: Gartner, [Report Title], [Authors], [Publication Date]. You may also refer to the Content Compliance Policy to capture the required formatting.
Trademark Disclaimer (Gartner®)
GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and is used herein with permission. All rights reserved.
Objectivity Disclaimer
Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
(182 words)
- [Gartner Hype Cycle for Life Science R&D | IQVIA](/content/analyst-reports/report/gartner-hype-cycle-for-life-science-r-and-d/index.html): Gartner Hype Cycle report on emerging Life Science Manufacturing technologies (22 words)
- [Gartner Hype Cycle for Intelligent Health | IQVIA](/content/analyst-reports/report/gartner-hype-cycle-for-intelligent-health/index.html): Gartner Hype Cycle Report for Intelligent Health 2026 (20 words)
- [Gartner Hype Cycle for Healthcare and Life Science Data, Analytics and AI, 2026 | IQVIA](/content/analyst-reports/report/gartner-hype-cycle-for-healthcare-and-life-science-data.html): Gartner Hype Cycle for Life Science Data, Analytics and AI June 2, 2026. (31 words)
- [Forrester: The Sales Force Automation Landscape, Q2 2023 | IQVIA](/content/analyst-reports/report/forrester-the-sales-force-automation-landscape-q2-2023.html): Forrester The Sales Force Automation Landscape Q2 2023 (17 words)
- [Everest Group Life Sciences Sales and Marketing Operations PEAK Matrix Assessment 2023 | IQVIA](/content/analyst-reports/report/everest-group-life-sciences-sales-and-marketing-operations-peak-matrix-assessment-2023.html): In this research, Everest Group assessed 17 life sciences CX platform providers to deliver a comprehensive overview of the provider’s service focus, key Intellectual Property (IP)/solutions and domain investments. IQVIA was the highest-scoring provider named in the Leader category. (59 words)
- [media/iqvia/pdfs/library/white-papers/2026/placing-the-right-bets-defining-tailored-investment-strategies-for-pharma-launch-pdf.html](/content/media/iqvia/pdfs/library/white-papers/2026/placing-the-right-bets-defining-tailored-investment-strategies-for-pharma-launch-pdf.html) (2,747 words)
- [Beyond weight loss: Preserving muscle during pharmacotherapy of obesity | IQVIA](/content/locations/emea/blogs/2025/06/beyond-weight-loss/index.html): This blog explores innovative pharmacotherapies for obesity that not only promote weight loss but also preserve muscle mass, enhancing overall health and physical function. (2,920 words)
- [Outlook for Obesity in 2026: From Consolidation to Acceleration | IQVIA](/content/locations/emea/blogs/2026/01/outlook-for-obesity-in-2026/index.html): Discover the key trends shaping obesity treatment in 2026, including breakthrough GLP-1 therapies, oral obesity drugs, market innovation, policy changes, and real-world evidence. Explore how new medications, digital health, and global guidelines are accelerating chronic disease management and transforming access to care. (3,311 words)
- [Specialty Brands: The Pharmaceutical Industry's Salvation, or Impediments to Future Innovation?](/content/media/quintilesims/pdfs/specialty-brands-the-pharmaceutical-industry-salvation-or-impediments-to-future-innovation-pdf.html) (2,197 words)
- [Launch Landscape – Monthly Launch Tracker](/content/media/iqvia/pdfs/us/us-location-site/library/iqvia-monthly-launch-tracker-pdf.html) (2,578 words)
- [Global R&D Trends 2026 | IQVIA](/content/insights/the-iqvia-institute/reports-and-publications/reports/global-r-and-d-trends-2026/index.html): Explore global R&D trends shaping biopharma innovation, including funding, clinical trials, AI-driven development, and productivity in a complex policy landscape. (953 words)
- [Outlook for obesity to 2035 | IQVIA](/content/locations/emea/blogs/2026/09/outlook-for-obesity-to-2035/index.html): Explore the future of obesity treatment to 2035, from GLP-1 therapies and obesity medicines to personalised care, diagnostics and healthcare policy (1,521 words)
- [Locations | IQVIA](/content/locations/index.html): As a global community, IQVIA continuously invests and commits to advancing human health. (168 words)
- [Suppliers | IQVIA](/content/about-us/suppliers/index.html): IQVIA is committed to sustainable business practices for our suppliers. (325 words)
- [The EU Biotech Act (Part 1): A summary and review of its incentives | IQVIA](/content/locations/emea/blogs/2026/04/the-eus-biotech-act-proposal-a-summary-and-review-of-its-incentives.html): The EU’s Biotech Act aims to boost innovation, investment and manufacturing in Europe. We unpack its incentives, funding pilots and regulatory reforms. (2,163 words)
- [New Demand in an Old Market | IQVIA](/content/locations/united-states/blogs/2023/08/new-demand-in-an-old-market/index.html): Explore the explosive growth of the GLP-1 market that is transforming the entire pharmaceutical industry. (1,692 words)
- [The hidden growth opportunities behind MMM | IQVIA](/content/locations/emea/blogs/2026/09/the-hidden-growth-opportunities-behind-mmm/index.html): Explore the evolving role of Marketing Mix Modeling (MMM) in pharmaceutical marketing. This blog highlights its strategic value across the Middle East and EU4+UK regions. It emphasizes the transition from traditional promotional methods to data-driven, AI-enabled approaches that optimize investments and engagement. (1,999 words)
- [media/iqvia/pdfs/library/fact-sheets/iqvia-institute-global-use-of-medicines-2023-report-01-23-research-factsheet-regions-pdf.html](/content/media/iqvia/pdfs/library/fact-sheets/iqvia-institute-global-use-of-medicines-2023-report-01-23-research-factsheet-regions-pdf.html) (1,049 words)
- [Real World & Health Data Sets | IQVIA](/content/solutions/real-world-evidence/real-world-data-and-insights/index.html): Richer real world data insights can drive smarter decisions. Real world evidence is accelerating and informing almost every area of research and commercialization. (833 words)
- [AI Readiness and Operating Models: From Data Foundation to Trusted Impact | IQVIA](/content/blogs/2026/09/ai-readiness-and-operating-models/index.html): Almost every organization in life sciences is using AI in some form. However, very few organizations can point to a broad lift in decision quality or cycle time, outside of pockets such as drug discovery. e.g., where AI-driven target identification and molecular design are showing real, measurable gains in Phase I. (2,255 words)
- [The Distance Between Diagnosis and Quality Care | IQVIA](/content/locations/united-states/blogs/2026/09/the-distance-between-diagnosis-and-quality-care/index.html): Explore rural healthcare access barriers across chronic care, telehealth, specialtycare, and acute care. (2,254 words)
- [Menopause, HRT and Healthy Ageing: Understanding the Evolving Women's Health Market in the UK | IQVIA](/content/locations/united-kingdom/blogs/2026/08/menopause-hrt-and-healthy-ageing/index.html): Explore how rising menopause awareness, accelerating HRT uptake, evolving treatment patterns and a greater focus on healthy ageing are reshaping the UK women's health market, creating new opportunities for life sciences organisations. (2,484 words)
- [Digital Health Trends 2024 | IQVIA](/content/blogs/2025/01/institute-blog-digital-health-trends-2024/index.html): This blog offers five takeaways from the IQVIA Institute's recent report on Digital Health Trends 2024. (1,631 words)
- [Model Bias and Governance in Healthcare Insurance: Why It Matters Now | IQVIA](/content/blogs/2025/09/model-bias-and-governance-in-healthcare-insurance/index.html): Artificial intelligence (AI) is transforming healthcare insurance. From streamlining underwriting to refining pricing models, data-driven decision-making is integral to competitiveness. (1,519 words)
- [IQVIA.ai Platform | IQVIA](/content/es-co/solutions/innovative-models/artificial-intelligence-and-machine-learning/iqvia-ai-platform/index.html): IQVIA.ai is an AI assistant and agent marketplace designed specifically for life sciences organizations to help them work more efficiently, make better decisions and scale AI responsibly across clinical, commercial and real-world operations. It combines natural language AI assistance with an agent marketplace that enables customers to deploy ready-to-use or configurable agents aligned to their workflows. (1,059 words)
- [The evolution of pharma engagement as AI becomes a front door to medical information | IQVIA](/content/locations/emea/blogs/2026/03/the-evolution-of-pharma-engagement-as-ai-becomes-a-front-door-to-medical-information.html): As AI becomes the front door to medical information, explore how generative AI is reshaping pharma engagement, go‑to‑market models, and HCP decision‑making. (1,801 words)
- [Commitment to Global Health | IQVIA](/content/about-us/commitment-to-global-health/index.html): IQVIA is working to advance public health in partnership with other companies, governments, and non-governmental organizations, from fighting opioid addiction to addressing antibiotic resistance. (1,362 words)
- [Biopharma M&A: Outlook for 2026 | IQVIA](/content/locations/emea/blogs/2026/01/biopharma-m-and-a-outlook-for-2026/index.html): Explore key biopharma M&A trends for 2026, including deal value forecasts, funding shifts, policy impacts, and the forces shaping global pharma innovation. (2,089 words)
- [Partner Programs | IQVIA](/content/solutions/technologies/partner-programs/index.html): IQVIA is building one of the healthiest partner ecosystems in the industry with programs that drive mutual success across the value chain. (763 words)
- [Events and Webinars | IQVIA](/content/events/index.html): Visit IQVIA at any of the events or webinars ongoing across the globe to discuss how we can help move your business forward and take what's possible in human health further. (159 words)
- [media/iqvia/pdfs/library/articles/2025/achieving-launch-excellence-in-the-evolving-obesity-market-pharmalive-pdf.html](/content/media/iqvia/pdfs/library/articles/2025/achieving-launch-excellence-in-the-evolving-obesity-market-pharmalive-pdf.html) (1,683 words)
- [Nordics | IQVIA](/content/locations/nordics/index.html): IQVIA provides information and technology in integrated solutions in order to maximize innovation and advance healthcare. (997 words)
- [Analyst Reports | IQVIA](/content/analyst-reports/index.html): Analyst Reports (350 words)
- [Compléments alimentaires en France : l'innovation et le digital redessinent le paysage concurrentiel | IQVIA](/content/fr-fr/locations/france/blogs/2026/04/complements-alimentaires-en-france/index.html): Découvrez les tendances clés du marché des compléments alimentaires en France : croissance 2025, rôle de l’innovation et impact du digital selon IQVIA.
Le marché des compléments alimentaires en France évolue : innovation produit, vente en ligne et nouveaux relais de croissance consumer health analysés par IQVIA. (759 words)
- [library/index.html](/content/library/index.html) (127 words)
- [Medical Device Recall & Field Action Services | IQVIA](/content/sub-brands/medtech/commercialization/iqvia-medtech-recall-and-field-action-program/index.html): Manage global recalls and field actions with IQVIA MedTech experts. Streamline medical device remediation, compliance, and patient communication worldwide. (1,009 words)
- [AI Driven HCP and Patient Profiling - Healthcare | IQVIA](/content/solutions/real-world-evidence/health-data-apps-and-ai/ai-driven-hcp-and-patient-profiling/index.html): Improve clinical healthcare decision making with AI-driven disease modeling and patient profiling. (841 words)
- [Building Trust through Governance: Realistic AI Deployment in Drug Safety | IQVIA](/content/blogs/2025/12/building-trust-through-governance/index.html): In this two-part blog, Marie Flanagan, Regulatory and AI Governance Lead, IQVIA Safety Technologies, explores how IQVIA's deployment of AI governance into pharmacovigilance (PV) systems has valuable lessons for pharma companies working in this complex environment. (1,005 words)
- [MIDAS® | IQVIA](/content/solutions/commercialization/data-and-information-management/midas/index.html): Gain market insight at a global and individual market level, with an analytics platform built on sales and medical data from over 90 countries (934 words)
- [Assessing Availability of New Drugs in Europe, Japan, and the U.S. | IQVIA](/content/insights/the-iqvia-institute/reports-and-publications/reports/assessing-availability-of-new-drugs-in-europe-japan-and-the-us.html): This report from the IQVIA Institute on Assessing Availability of New Drugs in Europe, Japan, and the U.S. aims to understand the current landscape of NAS approvals and availability across these regions and to identify areas where policy reforms can enhance patient access. The proportion of total NASs approved by each region and how quickly each region approved NASs is evaluated. Subsequently, the rate at which NASs achieve availability after approval and how long it takes to become available by country is assessed. (840 words)
- [IQVIA Middle East & Africa | IQVIA](/content/locations/middle-east-and-africa/index.html): The IQVIA team in the Middle East and Africa works to provide clarity in these dynamic markets. Our vast experience, local team of healthcare professionals, and global pool of resources give us the knowledge and understanding to help clients navigate through the local cultural and regulatory nuances, and respond to new market realities quickly, effectively, and with more precision. (345 words)
- [Analytics Research Accelerator | IQVIA](/content/solutions/real-world-evidence/health-data-apps-and-ai/analytics-research-accelerator/index.html): Rapidly identify, access, and explore patient data and cohorts with Analytics Research Accelerator. Assess data feasibility and health data resources. (371 words)
- [Health Data Transformation | IQVIA](/content/en-gb/solutions/real-world-evidence/health-data-transformation/index.html): With IQVIA's comprehensive data solutions expertise (data transformation, curation, privacy, NLP and OMOP conversions) you can structure, normalize, de-identify and transform your disparate data sources into analytics-ready output. Empowering your teams to concentrate on analysis, gain novel insights and deliver business value to improve drug development, population-level analysis, health delivery and patient outcomes. (904 words)
- [Nordics | IQVIA](/content/it-it/locations/nordics/index.html): IQVIA provides information and technology in integrated solutions in order to maximize innovation and advance healthcare. (969 words)
- [Optichannel Won’t Fix Omnichannel’s Execution Gap | IQVIA](/content/locations/united-states/blogs/2026/07/optichannel-wont-fix-omnichannels-execution-gap/index.html): Optichannel will not solve execution gaps. Better omnichannel execution drives stronger HCP engagement and trust. (1,904 words)
- [The outlook for obesity from 2026 to 2030 | IQVIA](/content/locations/emea/blogs/2026/04/the-outlook-for-obesity-from-2026-to-2030/index.html): From oral GLP‑1s to real‑world evidence, discover how innovation, competition and access will shape the obesity medicines market through 2030. (1,648 words)
- [blogs/index.html](/content/blogs/index.html) (164 words)
- [Real World Evidence | IQVIA](/content/solutions/real-world-evidence/index.html): Real world data and advanced technologies are shortening timelines, improving the impact of research investments, and helping therapies reach patients faster. (1,325 words)
- [Everest Group Life Sciences Customer Experience Platforms (CXP) PEAK Matrix® Assessment 2023 | IQVIA](/content/analyst-reports/report/everest-group-life-sciences-customer-experience-platforms-peak-matrix-assessment-2023.html): Everest Group Life Sciences Customer Experience Platforms PEAK Matrix Assessment 2023 (153 words)
- [media/iqvia/pdfs/library/articles/obesity-interest-sparks-dealmaking-activity-ungated.html](/content/media/iqvia/pdfs/library/articles/obesity-interest-sparks-dealmaking-activity-ungated.html) (948 words)
- [media/iqvia/pdfs/institute-reports/measuring-the-estimated-size-of-the-us-pharmaceutical-market-on-a-net-manufacturer-price-basis/iqvia-measuring-the-us-pharma-market-tech-note-03-26-forweb-pdf.html](/content/media/iqvia/pdfs/institute-reports/measuring-the-estimated-size-of-the-us-pharmaceutical-market-on-a-net-manufacturer-price-basis/iqvia-measuring-the-us-pharma-market-tech-note-03-26-forweb-pdf.html) (2,207 words)
- [Decentralized Clinical Trial Platforms Provider Compendium Report 2024 | IQVIA](/content/analyst-reports/report/decentralized-clinical-trial-platforms-provider-compendium-report-2024.html): This compendium provides detailed and fact-based snapshots of 22 DCT providers. Each profile offers a comprehensive picture of the provider’s offerings, technology solutions, key clients, recent developments, and investments. (47 words)
- [IQVIA United Kingdom | IQVIA](/content/locations/united-kingdom/index.html): Through the IQVIA CORE(TM) and our strategic collaborations with the NHS and life sciences, we are committed to bring UK Healthcare forward.
(306 words)
- [Everest Group AI-deas to Action: Operationalizing Generative AI in Life Sciences - Focus on IQVIA | IQVIA](/content/analyst-reports/report/everest-group-ai-deas-to-action/index.html): IQVIA has been named a Front-runner in the new Everest Group report AI-deas to Action: Operationalizing Generative AI in Life Sciences. (85 words)
- [IQVIA and Medera to Advance Cardiac Gene Therapy and Human-Based Drug Discovery | IQVIA](/content/newsroom/2026/08/iqvia-and-medera-to-advance-cardiac-gene-therapy-and-human-based-drug-discovery.html):
RESEARCH TRIANGLE PARK, N.C. and Boston, Mass. — August 4, 2026 — IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, and Medera Inc. (“Medera”), a clinical-stage biopharmaceutical company pioneering next-generation therapeutics for cardiovascular disease, today announced a strategic collaboration to accelerate the development of cardiac gene therapies and human-based drug discovery platforms.
The collaboration brings together IQVIA’s global clinical trial and commercialization infrastructure with Medera’s pioneering platforms: Sardocor, focused on developing disease-modifying gene therapies for difficult-to-treat cardiovascular diseases, and Novoheart, a leader in engineered human-based cardiac tissue for disease modelling and drug screening.
Sardocor will leverage IQVIA’s regulatory and trial execution expertise to advance its FDA-cleared, first-in-human AAV-based gene therapy programs. IQVIA will support patient recruitment, data quality and regulatory filings, including applications for expedited FDA designations.
Novoheart’s mini-Heart platform is already instrumental in securing IND and Fast Track designations and offers a predictive, human-based alternative to animal testing. The platform is expanding into multiple organ systems to support drug discovery and safety testing under the FDA Modernization Act 2.0.
“By combining IQVIA’s global expertise with Medera’s mini-Heart platform and gene therapy programs, we can bring safer, more effective therapies to patients faster,” said Ronald Li, Co-Founder, Chairman & CEO of Medera. “This collaboration expands our reach, while reinforcing the scientific and regulatory momentum around human-based drug discovery and cardiac gene therapy innovation.”
About IQVIA
IQVIA (NYSE:IQV) is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA’s portfolio of solutions are powered by IQVIA Connected Intelligence™ to deliver actionable insights and services built on high-quality health data, Healthcare-grade AI®, advanced analytics, the latest technologies and extensive domain expertise. IQVIA is committed to using AI responsibly, with AI-powered capabilities built on best-in-class approaches to privacy, regulatory compliance and patient safety, and delivering AI to the high standards of trust, scalability and precision demanded by the industry. With approximately 94,000 employees in over 100 countries, including experts in healthcare, life sciences, data science, technology and operational excellence, IQVIA is dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide.
IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.
About Medera Inc.
Medera is a clinical-stage biopharmaceutical company focused on targeting difficult-to-treat and currently incurable diseases by developing next-generation therapeutics. Medera operates via two business units: Sardocor, its clinical development arm advancing a pipeline of cardiac gene therapy trials (HFpEF, HFrEF, DMD-CM), and Novoheart, its preclinical subsidiary pioneering the world’s first and award-winning “mini-Heart” technology for human-based disease modelling, drug discovery, and toxicity testing. Novoheart’s platforms have already supported FDA IND and Fast Track designations, and the company is advancing a broader pipeline of gene therapy, cell therapy, and small molecule candidates. For more information, visit www.medera.bio.
Contacts
(602 words)
- [Insights | IQVIA](/content/insights/index.html): IQVIA's point of view on the topics and trends making an impact around the world and bringing new ideas and innovative approaches to the people who can use them now. (314 words)
- [U.S. Medicine Use Trends 2026 | IQVIA](/content/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026/index.html): Analysis of U.S. medicine use, spending, and access trends, highlighting rising costs, innovation drivers, patient burden, and the evolving impact of healthcare policies through 2030. (979 words)
- [Why Pharma Is Going Direct to Consumers | IQVIA](/content/locations/united-states/blogs/2025/08/why-pharma-is-going-direct-to-consumers/index.html): Why pharma is shifting to direct-to-consumer models amid policy reform and evolving patient expectations. (1,665 words)
- [media/iqvia/pdfs/us/fact-sheet/2023/health-equity-and-social-determinants-of-health-for-payers-pdf.html](/content/media/iqvia/pdfs/us/fact-sheet/2023/health-equity-and-social-determinants-of-health-for-payers-pdf.html) (842 words)
- [Nordics | IQVIA](/content/pt-pt/locations/nordics/index.html): IQVIA provides information and technology in integrated solutions in order to maximize innovation and advance healthcare. (1,118 words)
- [AIM Research Top Pharma Commercial Analytics Platforms 2025 | IQVIA](/content/analyst-reports/report/aim-research-top-pharma-commercial-analytics-platforms-2025.html): Commercial Analytics AIM Research Top Pharma Commercial Analytics Platforms 2025 March 30, 2025 Analyst Report (156 words)
- [Global Oncology Trends 2025 | IQVIA](/content/en-gb/insights/the-iqvia-institute/reports-and-publications/reports/global-oncology-trends-2025/index.html): This annual trend report from the IQVIA Institute profiles the current state of research and development in oncology, including key mechanisms, targets, and cancer types being investigated as well as pointing to some novel areas which are only just emerging. We also look at metrics of clinical development productivity. (1,061 words)
- [Argentina | IQVIA](/content/es-ar/locations/argentina/index.html): IQVIA es líder mundial en el uso de datos, tecnología, análisis avanzado y experiencia humana para ayudar a los clientes a impulsar la industria de la salud y la salud humana. Junto con las empresas a las que prestamos servicios, estamos habilitando un sistema de atención médica más moderno, más eficaz y más eficiente, y estamos creando soluciones innovadoras que transforman los resultados empresariales y de los pacientes. (206 words)
- [Everest Group Life Sciences Clinical Data & Analytics Platforms PEAK Matrix Assessment 2023 | IQVIA](/content/analyst-reports/report/everest-group-life-sciences-clinical-data-analytics-platforms-peak-matrix-assessment-2023.html): This study of 14 providers of clinical data & analytics platforms from Everest Group names IQVIA as a Major Contender. The study assesses the platforms' impact on clinical trials, patient care, treatment outcomes, and health system efficiency. (60 words)
- [Interleukin Inhibitors to Continue Driving Psoriasis Market Growth | IQVIA](/content/blogs/2021/02/interleukin-inhibitors-to-continue-driving-psoriasis-market-growth.html): GMI's Forecast Link analyses the future market trends for the Psoriasis market (898 words)
- [Medical Devices Speaker Programs: A Smarter, Compliant Model with IQVIA MedTech | IQVIA](/content/library/case-studies/medical-devices-speaker-programs/index.html): Discover how IQVIA MedTech helped a medical devices company modernize speaker programs to improve compliance, efficiency, and satisfaction. Download the IQVIA MedTech case study. (484 words)
- [Global Oncology Trends 2025 | IQVIA](/content/bg-bg/insights/the-iqvia-institute/reports-and-publications/reports/global-oncology-trends-2025/index.html): This annual trend report from the IQVIA Institute profiles the current state of research and development in oncology, including key mechanisms, targets, and cancer types being investigated as well as pointing to some novel areas which are only just emerging. We also look at metrics of clinical development productivity. (878 words)
- [The role of Patient Organizations and Medical Specialty Societies in the Development of AI-based Clinical Decision Support Tools to Improve Patient Care | IQVIA](/content/locations/united-states/blogs/2024/11/the-role-of-patient-organizations-and-medical-specialty-societies-in-the-development-of-ai-based.html): Learn more about the role of medical specialty societies and patient organizations in the development of AI-based Clinical Decision Support Tools (CDSTs) that can enhance patient care by closing clinical gaps and improving outcomes. (868 words)
- [Global Oncology Trends 2025 | IQVIA](/content/uk-ua/insights/the-iqvia-institute/reports-and-publications/reports/global-oncology-trends-2025/index.html): This annual trend report from the IQVIA Institute profiles the current state of research and development in oncology, including key mechanisms, targets, and cancer types being investigated as well as pointing to some novel areas which are only just emerging. We also look at metrics of clinical development productivity. (873 words)
- [The new conversation on weight: what German social media reveals about attitudes to obesity medicines | IQVIA](/content/locations/emea/blogs/2026/02/the-new-conversation-on-weight/index.html): German patients are reshaping obesity care online. Learn how social media insights reveal treatment expectations, unmet needs, and market opportunities. (1,325 words)
- [Search | IQVIA](/content/search/index.html): Search (9 words)
- [Available IQVIA Data | IQVIA](/content/insights/the-iqvia-institute/available-iqvia-data/index.html): Through collaboration with the IQVIA Institute, researchers have access to a broad range of proprietary databases and tools to support independent research, discovery work and requirement development for future funded studies. This page offers a list of available data. (835 words)
- [Now in Effect: 3 Key Functions Your eTMF Needs to Meet New EMA Regulations | IQVIA](/content/blogs/2022/06/now-in-effect-3-key-functions-your-etmf-needs-to-meet-new-ema-regulations.html): EMA's new clinical trial regulation is meant to foster innovation through a simpler clinical trial application process across the EU while increasing transparency of clinical trials and their results. As it takes effect this year, we consider three key functions that an electronic Trial Master File must have to achieve compliance and maintain organizational success. (1,042 words)
- [Landing | IQVIA](/content/landing/index.html): Landing (6 words)
- [IQVIA at DIA 2022: DAY 2 Recap | IQVIA](/content/blogs/2022/06/iqvia-at-dia-2022-day-2-recap/index.html): It's that time of year again – the 2022 Drug Information Association (DIA) Global Annual Meeting kicked-off today in Chicago! As DIA returns to in-person programming, the IQVIA and Q2 Solutions teams are excited to join fellow research and development (R&D) stakeholders, regulators, patients and more as we come together to tackle global and local challenges impacting patients around the world. (635 words)
- [The Impact of Biosimilar Competition in Europe 2025 | IQVIA](/content/library/white-papers/the-impact-of-biosimilar-competition-in-europe-2025.html): 'The Impact of Biosimilar Competition in Europe' report series provides novel insights and key performance indicators (KPIs) on the European biosimilars market each year. (179 words)
- [The new shape of consumer health | IQVIA](/content/blogs/2026/05/the-new-shape-of-consumer-health/index.html): GLP-1s are accelerating a shift from treatment to health optimization. Discover what it means for consumer health growth and industry strategy. (1,201 words)
- [Global R&D Trends 2026 | IQVIA](/content/en-gb/insights/the-iqvia-institute/reports-and-publications/reports/global-r-and-d-trends-2026/index.html): Explore global R&D trends shaping biopharma innovation, including funding, clinical trials, AI-driven development, and productivity in a complex policy landscape. (1,080 words)
- [Tip of the Iceberg: Economic and Environmental Impact of the Vaccine Cold Chain | IQVIA](/content/locations/emea/library/white-papers/tip-of-the-iceberg-economic-and-environmental-impact-of-the-vaccine-cold-chain.html): Explore the hidden costs of the vaccine cold chain in Europe. Our white paper reveals the economic and environmental impact of vaccine distribution in the UK, Germany, and Spain, and how thermostable vaccines can reduce costs, improve logistics and importantly patient outcomes. (118 words)
- [IQVIA and Kexing Biopharm Expand Strategic Collaboration to Accelerate Global Biosimilar Development using AI-Enabled Capabilities | IQVIA](/content/newsroom/2026/05/iqvia-and-kexing-biopharm-expand-strategic-collaboration.html): RESEARCH TRIANGLE PARK, N.C. – May 13, 2026 – IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, is advancing its strategic collaboration with Kexing Biopharm to support a global, multi-product biosimilar development and commercialization program. Kexing Biopharm (Stock Code: 688136.SH) is an innovative biopharmaceutical enterprise mainly engaged in the R&D, production and sales of recombinant protein drugs and microecological preparations.
The collaboration is designed to support Kexing’s global expansion by bringing together IQVIA’s end-to-end capabilities across the development lifecycle. By aligning clinical development, regulatory strategy, advanced analytics and commercialization under a coordinated global approach, the program aims to accelerate biosimilar development for international markets while upholding rigorous standards for quality and scientific integrity.
In parallel, the collaboration integrates IQVIA’s AI-enabled clinical trial capabilities to enhance speed, efficiency and confidence in decision-making throughout development. The use of AI across key activities — from protocol design to site identification and study conduct — will help streamline execution and improve overall trial performance.
“Through this collaboration, we are supporting Kexing as it progresses its global biosimilar development efforts,” said Brian Mi, President, Asia Pacific, IQVIA. “IQVIA brings deep biosimilar expertise, global execution capabilities and AI-powered solutions to accelerate Kexing’s global expansion strategy.”
The collaboration reflects IQVIA’s ability to integrate science, insight and execution to help biosimilar developers navigate global complexity with confidence.
“This strategic collaboration will accelerate Kexing’s internationalization strategy and we are highly confident in its prospects,” said Yanqing Zhao, General Manager, Kexing Biopharm. “IQVIA’s scale, global data resources, AI capabilities, patient insights and clinical expertise will support the optimization of trial design, mitigation of regulatory risk and improvement of overseas registration efficiency.”
For more information, visit IQVIA.com.
About IQVIA
IQVIA (NYSE:IQV) is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA’s portfolio of solutions are powered by IQVIA Connected Intelligence™ to deliver actionable insights and services built on high‑quality health data, Healthcare‑grade AI®, advanced analytics, the latest technologies and extensive domain expertise. IQVIA is committed to using AI responsibly, with AI‑powered capabilities built on best‑in‑class approaches to privacy, regulatory compliance and patient safety, and delivering AI to the high standards of trust, scalability and precision demanded by the industry. With approximately 93,000 employees in over 100 countries, including experts in healthcare, life sciences, data science, technology and operational excellence, IQVIA is dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide.
IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy‑enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.
About Kexing Biopharm
Kexing Biopharm (Stock Code: 688136.SH) is a leading Internationalization biopharmaceutical company specializing in the research, manufacture, and commercialization of innovative medicines combining recombinant proteins, antibodies, and targeted delivery therapies, etc. Harnessing proprietary technology platforms, Kexing pioneers novel targeted biological therapies and advanced drug delivery systems to address critical unmet needs in oncology, autoimmune and infectious diseases, making transformative impact on patients. Driven by a dual strategic focus on breakthrough innovation and global outreach, Kexing is committed to becoming a world-class leader in bringing high-quality pharmaceutical solutions to patients worldwide.
Contacts:
Kerri Joseph, IQVIA Investor Relations
kerri.joseph@iqvia.com
+1.973.541.3558
Alissa Maupin, IQVIA Media Relations
alissa.maupin1@iqvia.com
+1.919.923.6785
(646 words)
- [Ready, Set, Launch: The Science of Pre-Launch Excellence | IQVIA](/content/locations/united-states/blogs/2025/10/ready-set-launch-the-science-of-pre-launch-excellence.html): Explore strategies to optimize pharmaceutical pre-launch planning and drive early patient and provider engagement. (2,020 words)
- [Evolving Beyond the PBS: Exploring Australia’s Private Medicines Market | IQVIA](/content/locations/australia-and-new-zealand/library/white-papers/evolving-beyond-the-pbs/index.html): Explore the evolving landscape of Australia's private medicines market beyond the Pharmaceutical Benefits Schedule (PBS), focusing on non-PBS medicines like anti-obesity medications, medicinal cannabis treatments, and the impact of telehealth consultations and pharmacist prescribing on primary care and health ecosystems. (83 words)
- [CTFS Site Payments | IQVIA](/content/solutions/technologies/clinical-trial-financial-suite/ctfs-site-payments/index.html): IQVIA Technologies Clinical Trial Payments is a tech-enabled service offering, independent of IQVIA CRO services, that takes the burden of making payments to sites around the world. (913 words)
- [The IQVIA Institute for Human Data Science | IQVIA](/content/insights/the-iqvia-institute/index.html): The IQVIA Institute for Human Data Science contributes to the advancement of human health globally through timely research, insightful analysis and scientific expertise applied to granular non-identified patient-level data. (172 words)
- [media/iqvia/pdfs/library/white-papers/enhancing-patient-safety-a-paradigm-shift-through-early-ai-adoption-in-pharmacovigilance-workflows-pdf.html](/content/media/iqvia/pdfs/library/white-papers/enhancing-patient-safety-a-paradigm-shift-through-early-ai-adoption-in-pharmacovigilance-workflows-pdf.html) (1,755 words)
- [Drug Prices Have Become More Affordable to Most Patients, says U.S. Medicine Spending Study from the IQVIA Institute for Human Data Science | IQVIA](/content/newsroom/2020/08/drug-prices-have-become-more-affordable-to-most-patients-says-us-medicine-spending-study-from-the-iq.html): - The average amount paid out-of-pocket per prescription remains steady at $10.67, unchanged from 2018 and up only $0.33 since 2014, as high levels of generic drug use and greater use of manufacturer coupons offset higher costs
- A record share of branded prescriptions is being dispensed at $0 cost to the patient due to health insurance benefit design, wider use of generics and use of coupons
- A record high share of prescriptions with final out-of-pocket costs below $20, exceeding 90% for the third consecutive year
- About 4% of branded prescriptions have out-of-pocket costs above $125, down 1% in 2015, but still numbering more than 23 million prescriptions last year
- The coverage gap for Medicare patients has been closed, contributing to lower costs per prescription for all patients as costs are now 25% of the allowed price until the “catastrophic” annual out-of- pocket threshold is reached
DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- The vast majority of patients in the United States are experiencing lower out-of-pocket costs for their drugs, paying a smaller share of costs and seeing a downward trend in their costs on average. That’s according to the latest report from The IQVIA™ Institute for Human Data Science, Medicine Spending and Affordability in the U.S.: Understanding Patient Costs for Medicines. The improved affordability for patients is due to changes in health insurance benefit design, a higher use of generics, record low price increases on branded drugs and more patients reaching “catastrophic” coverage levels.
The public discussion about drug prices and expenses has focused on the rising costs. However, important parts of the conversation, specifically the actual out-of-pocket costs to patients, have been obscured by the complexities and lack of transparency of the current pricing system. The new report from the IQVIA Institute for Human Data Science provides context and clarity on the pricing of prescription medicines. The report includes information on the differing prices paid by different stakeholders and by patients with different kinds of insurance. Uniquely, the report combines prescription cost data with household income data to illustrate how affordability is a distinctly personal issue for patients and their families.
“Lower drug price growth and improvements in affordability to patients is a testament to the positive market dynamics of the American pricing system and the fact that manufacturers, health insurers and the intermediaries, such as wholesalers and benefits managers, have taken actions to reduce the burden of drug costs to patients,” said Murray Aitken, IQVIA senior vice president and executive director of the IQVIA Institute for Human Data Science. “The current pricing system is very complex, and understanding the amount spent on medicines requires considering a range of measures that apply to the different stakeholders in the drug chain, including manufacturers, payers, benefits managers, wholesalers and patients. We are hoping that our report will contribute to more transparency and understanding of the different levels of cost.”
Additional highlights of the Medicine Spending and Affordability in the U.S.: Understanding Patient Costs for Medicines report include:
- Total out-of-pocket costs for patients: A record $67 billion was paid out-of-pocket by patients for all prescriptions filled in retail pharmacies in 2019, up from $61 billion in 2015. This was mainly due to a higher volume of prescriptions, especially among those over 65.
- Out-of-pocket costs for Medicare patients: Medicare beneficiaries filling prescriptions under Part D are paying more out-of-pocket in total due to rising numbers of enrollees, and a larger share are paying more than $500 in annual costs.
- Medicare patients filling prescriptions under Part D paid $16.1 billion out-of-pocket in 2019, up 27% over the past 5 years. This is mostly due to the 8.3 million increase in population over 65 (18.2%) and 13.7% higher volume per person, offset by 5.2% lower per-prescription costs. The lower patient cost per prescription is due to the closing of the coverage gap, larger numbers hitting the “catastrophic” out-of-pocket threshold and greater use of generics.
- Annually, 90% of all patients pay less than $500 in out-of-pocket costs, but 20% of Medicare Part D patients pay more, in part due to their inability to offset costs through manufacturer coupons and plan design, as well as a greater disease burden and associated higher per capita medicine use by seniors.
- The cost of insulin: The cost of insulin to patients has been subject to much scrutiny and discussion of capping costs. Some patients filling prescriptions for insulin stand to benefit significantly from proposals to set a cap of $35 per prescription.
- Across all patients, the average out-of-pocket cost for an insulin prescription was $31 in 2019, down from a record high of $35.70 in 2015.
- Across all pay-types, 24% of prescriptions carried an out-of-pocket cost of more than $35, but 31% of Medicare and 58% of cash payments reached this level, compared to 22% for those commercially insured. This reflects plan design and cash costs that are based on list prices.
- If all patients nationally had insulin costs capped at $35 — per the Medicare Part D senior savings model for 2021 and some state plans — patients would have saved $837 million in out-of-pocket costs in 2019, including $279 million by Medicare beneficiaries, $326 million by the uninsured paying cash and $233 million by those with commercial insurance.
- Patient cost sensitivity: A growing public health concern is patients abandoning their new prescriptions and not following the physician’s recommendation for care. Abandonment occurs much more often at higher levels of patient out-of-pocket cost.
- In 2019, 9% of all new prescription starts were abandoned at retail pharmacy, representing patient care recommended by a physician but not received by the patient.
- While abandonment rates are less than 5% when the prescription carries no out-of-pocket cost, it rises to 45% when the cost is over $125 and 60% when the cost is over $500.
- In the case of diabetes, anticoagulants and oral cancer drugs, the average abandonment rate is 18% of all new therapy starts because more of these drugs carry higher costs.
The full version of the report, including a detailed description of the study methodology, is available at www.iqviainstitute.org/USMedsAffordability. The study was produced independently as a public service, without industry or government funding.
About the IQVIA Institute for Human Data Science
The IQVIA Institute for Human Data Science contributes to the advancement of human health globally through timely research, insightful analysis, and scientific expertise applied to granular non-identified patient-level data.
Fulfilling an essential need within healthcare, the Institute delivers objective, relevant insights and research that accelerate understanding and innovation critical to sound decision-making and improved human outcomes. With access to IQVIA’s institutional knowledge, advanced analytics, technology, and unparalleled data, the Institute works in tandem with a broad set of healthcare stakeholders to drive a research agenda focused on Human Data Science, including government agencies, academic institutions, the life sciences industry, and payers. More information about the IQVIA Institute can be found at www.IQVIAInstitute.org.
About IQVIA
IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions, and contract research services to the life sciences industry. Formed through the merger of IMS Health and Quintiles, IQVIA applies human data science — leveraging the analytic rigor and clarity of data science to the ever-expanding scope of human science — to enable companies to reimagine and develop new approaches to clinical development and commercialization, speed innovation and accelerate improvements in healthcare outcomes. Powered by the IQVIA CORE™, IQVIA delivers unique and actionable insights at the intersection of large-scale analytics, transformative technology and extensive domain expertise, as well as execution capabilities. With approximately 67,000 employees, IQVIA conducts operations in more than 100 countries.
IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors, and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200804005323/en/
Tor Constantino, IQVIA Media Relations (tor.constantino@iqvia.com)
+1.484.567.6732
Andrew Markwick, IQVIA Investor Relations (andrew.markwick@iqvia.com)
+1.973.257.7144
Source: IQVIA Holdings Inc.
RESEARCH TRIANGLE PARK, N.C. – August 17, 2026 – IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today announced that it has been ranked No. 1 in Everest Group’s “Top 50™ Pharmaceutical Technology Providers” report for 2026.
IQVIA earned the highest overall score among the 50 providers evaluated, receiving 96.8 out of 100. The ranking recognizes IQVIA’s broad technology coverage across the pharmaceutical value chain and its ability to support complex, highly regulated life sciences environments.
IQVIA was the only provider in the ranking with technology coverage across all six pharmaceutical value-chain areas assessed: drug discovery and research, clinical development, manufacturing operations, sales and marketing, supply chain and distribution and pharmacovigilance and safety.
This breadth of coverage helps customers connect capabilities across the product lifecycle, make better decisions and execute more effectively. IQVIA combines proprietary data and content, deep life sciences expertise, advanced technology and longstanding experience operating in highly regulated, privacy-sensitive environments to help customers address complex challenges with greater confidence. Biopharma customers are looking for more than individual technologies. They demand solutions that work together and a partner that understands the realities of their business.
To read the full Everest Group report, visit: “Top 50™ Pharmaceutical Technology Providers.”
To learn more about how IQVIA helps life sciences and healthcare organizations turn data, technology and AI into better outcomes, visit: www.iqvia.com.
About Everest Group
Everest Group is a leading global research firm helping business leaders make confident decisions. It guides clients through today’s market challenges and strengthens their strategies by applying contextualized problem-solving to their unique situations. This drives maximized operational and financial performance and transformative experiences. The Everest Group’s deep expertise and tenacious research focused on technology, business processes and engineering through the lenses of talent, sustainability and sourcing deliver precise and action-oriented guidance. Find further details and in-depth content at www.everestgrp.com.
About IQVIA
IQVIA (NYSE:IQV) is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA’s portfolio of solutions are powered by IQVIA Connected Intelligence™ to deliver actionable insights and services built on high-quality health data, Healthcare-grade AI®, advanced analytics, the latest technologies and extensive domain expertise. IQVIA is committed to using AI responsibly, with AI-powered capabilities built on best-in-class approaches to privacy, regulatory compliance and patient safety, and delivering AI to the high standards of trust, scalability and precision demanded by the industry. With approximately 94,000 employees in over 100 countries, including experts in healthcare, life sciences, data science, technology and operational excellence, IQVIA is dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide.
IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.
Contacts:
Kerri Joseph, IQVIA Investor Relations (kerri.joseph@iqvia.com)
+1.973.541.3558
Alissa Maupin, IQVIA Media Relations (alissa.maupin1@iqvia.com)
+1.919.923.6785
(581 words)
- [Decoding the Buzz Around Weight-loss Medications: Unpacking the Revolution of GLP-1 Medications | IQVIA](/content/blogs/2024/03/decoding-the-buzz-around-weight-loss-medications/index.html): Blog post to advertise OMOP PA capabilities in obesity studies. (1,892 words)
- [Enterprise Information Management | IQVIA](/content/solutions/commercialization/data-and-information-management/information-management/index.html): Purpose built information management for life science companies. Support business processes in real time with a reliable asset that transforms decision making. (513 words)
- [IQVIA Patient Experience Platform | IQVIA](/content/solutions/commercialization/patient-engagement-and-support/iqvia-patient-experience-platform/index.html): Helping patients personalize their healthcare and connect with caregivers can transform how care is delivered. Learn how IQVIA brings this future of personalized support with tech solutions for the devices patients already use. (362 words)
- [Obesity Deep Dive: The Unparalleled Launch Success of Mounjaro and Zepbound | IQVIA](/content/locations/united-states/blogs/2025/09/obesity-deep-dive-the-unparalleled-launch-success-of-mounjaro-and-zepbound.html): Explore how Mounjaro and Zepbound reshaped the anti-obesity market with data-driven launch success and strategy. (1,784 words)
- [Safety & Regulatory Compliance | IQVIA](/content/solutions/safety-regulatory-compliance/index.html): Better meet today’s complex, changing regulations with IQVIA’s integrated compliance solutions and spend more resources on getting and keeping products in market. (528 words)
- [Orchestrated Clinical Trials | IQVIA](/content/solutions/technologies/orchestrated-clinical-trials/index.html): IQVIA Technologies Orchestrated Clinical Trials (OCT) application suites can transform your clinical trials by creating efficiencies, improving workflow, increasing accuracy, and supporting intuitive guidance for safer and more efficient decentralized and hybrid trials. Our clinical technologies ease the burden on your sites and make it easier and more appealing for patients to enroll and remain engaged, produce faster trials to database lock, and speed time to market. (845 words)
- [The data you're already collecting may be worth more than you think | IQVIA](/content/nl-nl/sub-brands/medtech/blogs/2026/09/the-data-youre-already-collecting-may-be-worth-more-than-you-think.html): Discover how IQVIA Data Device Link connects medical device and diagnostic data with longitudinal healthcare data to generate evidence and demonstrate value. (1,311 words)
- [MedTech Consulting & Solutions | IQVIA](/content/sub-brands/medtech/index.html): Discover IQVIA MedTech solutions across regulatory, clinical research, reimbursement, quality assurance, and commercialization. Partner with experts to bring devices to market faster. (1,237 words)
- [Global Oncology Trends 2025 | IQVIA](/content/ko-kr/insights/the-iqvia-institute/reports-and-publications/reports/global-oncology-trends-2025/index.html): This annual trend report from the IQVIA Institute profiles the current state of research and development in oncology, including key mechanisms, targets, and cancer types being investigated as well as pointing to some novel areas which are only just emerging. We also look at metrics of clinical development productivity. (1,058 words)
- [Patient Tokenization | IQVIA](/content/locations/united-states/library/fact-sheets/patient-tokenization/index.html): Patient Tokenization anonymously links multiple disparate data sets together at the patient level, providing the most comprehensive view of the patient journey while maintaining a minimum risk of re-identification. Provides one common, consistent, anonymous patient identifier allowing you to analyze patient behavior with healthcare providers and easy linkage and integration with IQVIA's patient-level data assets. (49 words)
- [IQVIA AI – Smarter | Connected | Trusted | IQVIA](/content/solutions/innovative-models/artificial-intelligence-and-machine-learning/index.html): Learn how unparalleled data, domain expertise, and technologies enable AI-powered solutions that are purpose-built for healthcare. (801 words)
- [Insights Library - Blogs, White Papers, Case Studies | IQVIA](/content/insights/points-of-view/index.html): IQVIA's Insights on the topics and trends making an impact around the world and bringing new ideas and innovative approaches to the people who can use them now. (136 words)
- [Reports and Publications | IQVIA](/content/insights/the-iqvia-institute/reports-and-publications/index.html): Reports and Publications (1,214 words)
- [EMEA Thought Leadership | IQVIA](/content/locations/emea/emea-thought-leadership/index.html): EMEA Thought Leadership (601 words)
- [Brand and Portfolio Strategy | IQVIA](/content/solutions/commercialization/brand-and-portfolio-strategy/index.html): Plan your pharmaceutical brand strategy at every stage with approaches tailored to opportunities along the commercial continuum, from pre-launch to LOE. (805 words)
- [Understanding Insulin Market Dynamics in Low and Middle Income Countries | IQVIA](/content/insights/the-iqvia-institute/reports-and-publications/reports/understanding-insulin-market-dynamics-in-low-and-middle-income-countries.html): This report looks at the competitive landscape for insulin manufacturing in the 32 low- and middle-income countries where IQVIA audited data exist. (869 words)
- [IQVIA's Predictive Clinical Development provides sponsors with significant efficiencies to get treatments to market faster | IQVIA](/content/newsroom/2026/09/iqvia-predictive-clinical-development-provides-sponsors-with-significant-efficiencies.html): RESEARCH TRIANGLE PARK, N.C. – September 3, 2026 – IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence, today announced IQVIA Predictive Clinical Development, an AI-powered approach designed to help life sciences sponsors reduce avoidable delays and bring new therapies to patients up to two years faster.
Traditional approaches in clinical development no longer keep pace with increasing trial complexity.
IQVIA Predictive Clinical Development is built to eliminate them, accelerating every stage of the development lifecycle with measurable results:
- 33% faster study startup
- 1.7 times more patients recruited from our AI prioritized and Prime & Partner sites with
42% higher enrollment rates
- 50% faster data cleaning
- 45%+ reduced time between trial phases
IQVIA Predictive Clinical Development pairs IQVIA's proprietary data, deep regulatory expertise and best-in-class Healthcare-grade AI® with premier technologies from Anthropic, Amazon Web Services (AWS), Databricks, Microsoft, NVIDIA, Palantir and Snowflake orchestrated to drive agentic workflows.
"At a time when every moment matters for patients waiting on new therapies, IQVIA Predictive Clinical Development represents a fundamental shift," said Richard Staub, president of Research and Development Solutions at IQVIA. "We're helping customers make development faster, more predictable and of a higher quality — compressing timelines, accelerating decisions and speeding medicines to market."
IQVIA Predictive Clinical Development is enabled by IQVIA's clinical AI capabilities:
- Clinical Design & Planning Suite generates predictive insights to inform site selection, prioritizes sites including its Prime and Partner network and operationalizes the recruitment strategy to speed enrollment.
- Push Button Start-Up is an integrated and streamlined delivery model that applies standardization, automation and AI-enabled processes to accelerate the time to starting patient enrollment.
- Real-time Data Cleaning enables faster, more reliable, higher quality data to make confident decisions during and after a study. It brings clinical data together across multiple sources, drives greater efficiency and enables more rapid database locks.
IQVIA is uniquely positioned to change the trajectory of clinical development ultimately closing the gap between scientific discovery to patient care. As IQVIA extends its leadership in AI, new components will continue to expand Predictive Clinical Development across the entire development lifecycle, helping customers move faster with confidence.
To learn more about IQVIA Predictive Clinical Development, visit: Clinical Research & Development Solutions | IQVIA. To learn more about IQVIA AI agents, visit: Agentic AI | Life Sciences | IQVIA
About IQVIA
IQVIA (NYSE:IQV) is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA’s portfolio of solutions are powered by IQVIA Connected Intelligence™ to deliver actionable insights and services built on high-quality health data, Healthcare-grade AI®, advanced analytics, the latest technologies and extensive domain expertise. IQVIA is committed to using AI responsibly, with AI-powered capabilities built on best-in-class approaches to privacy, regulatory compliance and patient safety, and delivering AI to the high standards of trust, scalability and precision demanded by the industry. With approximately 94,000 employees in over 100 countries, including experts in healthcare, life sciences, data science, technology and operational excellence, IQVIA is dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide.
IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.
Contacts:
Kerri Joseph, IQVIA Investor Relations (kerri.joseph@iqvia.com)
+1.973.541.3558
Alissa Maupin, IQVIA Media Relations (alissa.maupin1@iqvia.com)
+1.919.923.6785
(657 words)
- [Nordics Solutions | IQVIA](/content/locations/nordics/solutions/index.html): Solutions (303 words)
- [The Growing Role of Real-World Evidence in Clinical Trials | IQVIA](/content/blogs/2026/05/the-growing-role-of-real-world-evidence-in-clinical-trials.html): Clinical development teams face growing pressure from longer timelines, rising complexity, and evolving regulatory expectations. Real‑world evidence can help you design more feasible trials, anticipate risk earlier, and strengthen evidence to support your trial development and regulatory decisions. Explore more in this blog. (1,061 words)
- [IQVIA and SCRI Collaborate to Accelerate Global Oncology Trials | IQVIA](/content/newsroom/2025/05/iqvia-and-scri-collaborate-to-accelerate-global-oncology-trials.html): RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, has announced a strategic collaboration with the contract research organization arm of Sarah Cannon Research Institute, SCRI Development Innovations, aimed at transforming oncology trials for biopharma partners worldwide. By combining the capabilities of IQVIA and SCRI Development Innovations, this collaboration will enhance clinical trial processes, eliminate operational hurdles, accelerate data delivery and expedite the availability of cutting-edge therapies to patients.
The collaboration leverages IQVIA’s global reach and precision in managing one in five oncology trials in the United States, along with its ability to seamlessly integrate data, technology and analytics. These capabilities are combined with SCRI Development Innovations' community oncology expertise, and enhanced operational model, Accelero, which expedites trial activation and enhances recruitment for SCRI sites in the United States. Additionally, the Accelero model seamlessly integrates data from the electronic health record to the electronic data capture systems for U.S. clinical trial data collection. Together, these strengths offer sponsors a more effective pathway to operationalize the development of innovative treatments for patients.
“We are excited to announce our collaboration with SCRI Development Innovations,” said Richard Staub, president of Research & Development Solutions at IQVIA. “This collaboration embodies our commitment to innovation, efficiency and delivering of superior outcomes for patients by bringing together the best of both organizations and eliminating the complexities often associated with multiple vendors. Together we will accelerate the development of new cancer therapies and improve outcomes for patients worldwide.”
“We are enthusiastic about the impact we can make in transforming clinical trial delivery through our collaboration with IQVIA,” said Dee Anna Smith, chief executive officer at Sarah Cannon Research Institute. “Through our accelerated operations model, Accelero, SCRI can alleviate the operational burden on research sites, enhance enrollment and expedite data delivery through our cutting-edge technology solutions. Additionally, we will leverage IQVIA’s global reach, expertise and capabilities in trial design and recruitment to provide a seamless global delivery model for our partners.”
The collaboration between IQVIA and SCRI Development Innovations marks a significant step forward in transforming oncology trial delivery globally. Visit IQVIA at Booth 14103 or SCRI at Booth 27022 during the American Society of Clinical Oncology (ASCO) Annual Meeting May 30 to June 3 in Chicago, Ill., to learn more about this innovative partnership to advance cancer research and improve patient outcomes.
About IQVIA
IQVIA (NYSE:IQV) is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA’s portfolio of solutions are powered by IQVIA Connected Intelligence™ to deliver actionable insights and services built on high-quality health data, Healthcare-grade AI®, advanced analytics, the latest technologies and extensive domain expertise. IQVIA is committed to using AI responsibly, with AI-powered capabilities built on best-in-class approaches to privacy, regulatory compliance and patient safety, and delivering AI to the high standards of trust, scalability and precision demanded by the industry. With approximately 88,000 employees in over 100 countries, including experts in healthcare, life sciences, data science, technology and operational excellence, IQVIA is dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide.
About Sarah Cannon Research Institute
Sarah Cannon Research Institute (SCRI) is one of the world’s leading oncology research organizations conducting community-based clinical trials. Focused on advancing therapies for patients over the last three decades, SCRI is a leader in drug development. It has conducted more than 850 first-in-human clinical trials since its inception and contributed to pivotal research that has led to the majority of new cancer therapies approved by the FDA in the past decade. SCRI’s research network brings together more than 1,300 physicians who are actively accruing patients to clinical trials at more than 250 locations in 24 states across the U.S. Visit scri.com to learn more.
Contacts
Media Contacts
IQVIA:
Kerri Joseph, IQVIA Investor Relations (kerri.joseph@iqvia.com) +1.973.541.3558
Alissa Maupin, IQVIA Media Relations (alissa.maupin1@iqvia.com) +1.919.923.6785
SCRI:
Becca Gelman, Marketing & Public Relations (Becca.Gelman@scri.com)
(681 words)
- [media/iqvia/pdfs/institute-reports/orphan-drugs-in-the-united-states-exclusivity-pricing-and-treated-populations-pdf.html](/content/media/iqvia/pdfs/institute-reports/orphan-drugs-in-the-united-states-exclusivity-pricing-and-treated-populations-pdf.html) (1,496 words)
- [SmartSolve® Deviation Management | IQVIA](/content/library/fact-sheets/iqvia-smartsolve-deviation-management/index.html): SmartSolve® Deviation Management empowers pharmaceutical organizations to resolve deviations quickly and accurately while maintaining regulatory compliance. The AI-enabled platform integrates quality processes, risk assessment, and analytics for proactive, end-to-end quality management. (182 words)
- [Prevent Disclosure of IQVIA Data | IQVIA](/content/about-us/third-party-access-program/tpa-program-for-third-party-vendors/helpful-hints/prevent-disclosure-of-iqvia-data/index.html): IQVIA would like to share ideas that other Vendors have found useful in complying with the restrictions and obligations of the IQVIA Third Party Access Limited License Agreement. Vendors are required to take all reasonable steps necessary to protect IQVIA Data from unauthorized use, access, disclosure, misappropriation, or misuse. Preventing inappropriate disclosure of IQVIA Data is one step towards ensuring compliance. Below are some hints to help you do this. (321 words)
- [Launch Strategy and Management | IQVIA](/content/solutions/commercialization/launch-strategy-and-management/index.html): Identify critical launch factors and understand the competitive market environment. Make the right decisions pre-launch and position your product for success. (547 words)
- [Digital Health | IQVIA](/content/solutions/innovative-models/digital-health/index.html): Whether you see potential in operations, or an entirely new path for your business, IQVIA can help you harness digital in the right way. (602 words)
- [Neurology MedTech Consulting & Therapeutic Expertise | IQVIA MedTech | IQVIA](/content/sub-brands/medtech/therapeutic-areas/neurology-medtech-consulting/index.html): Explore IQVIA's neurology MedTech consulting expertise across neurological devices, neurosurgical technologies, clinical research, regulatory strategy, and commercialization. (1,134 words)
- [Omnichannel Engagement in Pharma: Harnessing the Power of Generative AI | IQVIA](/content/blogs/2024/10/omnichannel-engagement-in-pharma/index.html): Discover how AI and generative AI are revolutionizing omnichannel engagement in pharma, enhancing customer experiences, and driving better health outcomes. (1,171 words)
- [IQVIA Connected Healthcare Platform | IQVIA](/content/locations/emea/iqvia-connected-healthcare-platform/index.html): Explore IQVIA's innovative Connected Healthcare Platform, designed to enhance patient outcomes and streamline healthcare operations with advanced data analytics and integration capabilities. (276 words)
- [OneKey - Nordics | IQVIA](/content/locations/nordics/solutions/pharma/onekey/index.html): OneKey is the most accurate and complete syndicated healthcare professional database in the Nordics. It is built on structured and hierarchical brick systems and is compliant with all industry rules. (460 words)
- [IQVIA Hospital Information System | IQVIA](/content/locations/emea/iqvia-connected-healthcare-platform/iqvia-hospital-information-system/index.html): IQVIA Hospital Information System (HIS), is a comprehensive cloud-based technology solution designed to increase physician efficiency, reduce costs, facilitate regulatory compliance and promote standardization of care to build a safer, more convenient way of managing healthcare. (285 words)
- [Assessing the Biosimilar Void in the U.S. | IQVIA](/content/insights/the-iqvia-institute/reports-and-publications/reports/assessing-the-biosimilar-void-in-the-us/index.html): This report characterizes this biosimilar void and provides potential solutions for stakeholders to maximize biosimilar opportunity. Biosimilar competition provides cost savings and plays a vital role in the overall sustainability of the U.S. healthcare system. Understanding and addressing the biosimilar void is critical to realize the benefits these medicines bring. (743 words)
- [media/iqvia/pdfs/library/fact-sheets/smartsolve-complaint-management-pdf.html](/content/media/iqvia/pdfs/library/fact-sheets/smartsolve-complaint-management-pdf.html) (771 words)
- [Interactive Response Technology (IRT) for Clinical Trials | IQVIA](/content/solutions/technologies/patient-engagement-suite/interactive-response-technology/index.html): IQVIA IRT streamlines clinical trials with advanced randomization, drug supply management, and direct-to-patient capabilities for faster, flexible study execution. (607 words)
- [Insurers and Risk - United States | IQVIA](/content/locations/united-states/solutions/healthcare-solutions/insurer-and-risk-solutions/index.html): Assess and predict population risk with IQVIA data and technology. Manage costs, limit exposure, and drive growth. (592 words)
- [Reproductive Health | IQVIA](/content/solutions/therapeutics/reproductive-health/index.html): IQVIA's experience in Reproductive health, Women's Health, Urology, Reproduction, Fertility. (425 words)
- [IQVIA and Duke Clinical Research Institute announce strategic collaboration to advance clinical research in obesity and related conditions | IQVIA](/content/newsroom/2026/02/iqvia-and-duke-clinical-research-institute-announce-strategic-collaboration.html):
RESEARCH TRIANGLE PARK, N.C. — February 10, 2026 — IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, and the Duke Clinical Research Institute (DCRI), one of the world’s largest academic clinical research organizations with extensive experience designing and operationally executing large, complex multi-center clinical trials, are pleased to announce their new collaboration to enhance the conduct of clinical research in obesity and related cardiometabolic trials.
With the combined strength of two best-in-class organizations, this collaboration accelerates even the most sophisticated clinical programs and ensures coordinated, end-to-end support to sponsors, regulators, payers, patients and the broader medical community. By establishing the full operational framework up front, from governance to data flow to site-level execution, IQVIA and DCRI are able to quickly establish momentum on clinical trials with active support for a successful submission and beyond.
“By combining IQVIA’s operational excellence and global reach with DCRI’s academic rigor, we are setting a new standard for prospective collaboration between life science service companies and academic research organizations to accelerate clinical trial planning and delivery in obesity and related therapeutic areas,” said Dr. Jeffrey Spaeder, chief medical and scientific officer, IQVIA. “Uniting our combined clinical strength and complementary capabilities enables us to maximize trial efficiency, accelerate timelines and ultimately bring impactful therapies to patients faster.”
With more than 120 obesity trials conducted and more than 90,000 patients enrolled, IQVIA has supported clinical development, including operations, labs and patient support, for every FDA‑approved GLP‑1 therapy to date. This experience gives sponsors entering obesity and metabolic research a proven foundation. The collaboration between IQVIA and DCRI is poised to drive meaningful improvements in patient care and set new benchmarks for both operational and scientific excellence in clinical research.
“DCRI’s proven infrastructure for trial operations — including site activation, patient pre-screening, enrollment, retention and study management — along with our deep expertise in cardiometabolic and renal disease, enables us to design and execute trials that are both scientifically robust and operationally agile,” said Dr. Adrian Hernandez, executive director, DCRI. “Together with IQVIA, whose global scale and technology and AI capabilities enable efficient execution, we are expanding access to diverse patient populations and ensuring that our studies deliver meaningful results for sponsors, regulators, and most importantly, patients.”
Additional benefits of this strategic collaboration include:
- Expanded access to representative patient populations across 56 countries and more than 3,000 sites.
- Extended impact of thought leadership beyond immediate stakeholders bolstered by the involvement of DCRI clinical and data science and biostatistics faculty in presenting results.
- Leveraging of DCRI’s track record of pioneering research in GLP-1 receptor agonists and SGLT2 inhibitors, as well as IQVIA’s advanced analytics, electronic health records and real-world data in trial design and execution.
About IQVIA
IQVIA (NYSE:IQV) is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA’s portfolio of solutions are powered by IQVIA Connected Intelligence™ to deliver actionable insights and services built on high-quality health data, Healthcare-grade AI®, advanced analytics, the latest technologies and extensive domain expertise. IQVIA is committed to using AI responsibly, with AI-powered capabilities built on best-in-class approaches to privacy, regulatory compliance and patient safety, and delivering AI to the high standards of trust, scalability and precision demanded by the industry. With approximately 93,000 employees in over 100 countries, including experts in healthcare, life sciences, data science, technology and operational excellence, IQVIA is dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide.
IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.
About the Duke Clinical Research Institute (DCRI)
The DCRI, part of the Duke University School of Medicine, is the largest academic clinical research organization in the world. Our mission is to develop, share, and implement knowledge that improves global health through innovative clinical research. The institute conducts multinational clinical trials, manages major national patient registries, and performs landmark outcomes research. The DCRI is a pioneer in cardiovascular and pediatric clinical research and conducts groundbreaking clinical research across multiple other therapeutic areas, including infectious disease, neuroscience, respiratory medicine, and nephrology. To learn more, visit dcri.org.
Contacts:
Kerri Joseph, IQVIA Investor Relations (kerri.joseph@iqvia.com)
+1.973.541.3558
Alissa Maupin, IQVIA Media Relations (alissa.maupin1@iqvia.com)
+1.919.923.6785
Natalie Sayewich, DCRI Corporate Communications (natalie.sayewich@duke.edu)
+1.919.668.8787
(832 words)
- [IQVIA Announces Offering of Senior Notes | IQVIA](/content/newsroom/2026/09/iqvia-announces-offering-of-senior-notes/index.html): RESEARCH TRIANGLE PARK, N.C. – IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) today announced that its wholly owned subsidiary, IQVIA Inc. (the “Issuer”), intends to raise $2,000,000,000 through an offering of senior notes due 2034 (the “Notes”).
The proceeds from the Notes offering will be used to redeem in full the Issuer’s Senior 5.000% Notes due 2026, to repay a portion of the outstanding indebtedness under the Issuer’s revolving credit facility and to pay fees and expenses related to the Notes offering. The consummation of the Notes offering is subject to market and other customary conditions.
This press release does not constitute an offer to sell or the solicitation of an offer to buy the Notes, nor shall there be any offer, solicitation or sale of the Notes in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful. The Notes to be offered have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or the securities laws of any other jurisdiction and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act. The Notes are being offered only to persons reasonably believed to be qualified institutional buyers in the United States in reliance on Rule 144A under the Securities Act and outside the United States only to non-U.S. investors pursuant to Regulation S under the Securities Act. Any offer of the Notes will be made only by means of a private offering memorandum.
About IQVIA
IQVIA (NYSE:IQV) is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA’s portfolio of solutions are powered by IQVIA Connected Intelligence™ to deliver actionable insights and services built on high-quality health data, Healthcare-grade AI®, advanced analytics, the latest technologies and extensive domain expertise. IQVIA is committed to using AI responsibly, with AI-powered capabilities built on best-in-class approaches to privacy, regulatory compliance and patient safety, and delivering AI to the high standards of trust, scalability and precision demanded by the industry. With approximately 94,000 employees in over 100 countries, including experts in healthcare, life sciences, data science, technology and operational excellence, IQVIA is dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide.
IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures.
Forward Looking Statements
Certain statements in this press release are forward-looking statements. These statements involve a number of risks, uncertainties and other factors, including the failure to consummate the Notes offering, and potential changes in market conditions that could cause actual results to differ materially.
Contact:
Kerri Joseph, IQVIA Investor Relations (kerri.joseph@iqvia.com)
+1.973-541-3558
(552 words)
- [Real World Evidence - United States | IQVIA](/content/locations/united-states/solutions/life-sciences/real-world-evidence/index.html): Transform real world data into regulatory-grade evidence with IQVIA to accelerate approvals and market access. (674 words)
- [The Impact of Generative AI in Quality Management | IQVIA](/content/blogs/2024/06/the-impact-of-generative-ai-in-quality-management/index.html): Quality and regulatory teams can use generative AI to improve efficiency and performance. (765 words)
- [Nordics | IQVIA](/content/pl-pl/locations/nordics/index.html): IQVIA provides information and technology in integrated solutions in order to maximize innovation and advance healthcare. (906 words)
- [IQVIA Expert Engagement Platform - United States | IQVIA](/content/locations/united-states/solutions/life-sciences/medical-affairs/expert-engagement-platform/index.html): Unified KOL data and AI insights to optimize Medical Affairs engagement and prove measurable impact. (1,410 words)
- [Biomarkers for Idiopathic Pulmonary Fibrosis | IQVIA](/content/blogs/2024/04/biomarkers-for-idiopathic-pulmonary-fibrosis/index.html): Idiopathic pulmonary fibrosis (IPF) is a deadly disease with a poor prognosis, involving disabling symptoms and progressive loss of lung function. (1,187 words)
- [Karriere | IQVIA](/content/de-de/locations/germany/career-opportunities/index.html): Bei IQVIA unterstützen Sie unsere Kunden darin, dem Gesundheitswesen neue Impulse zu geben. Auf diesem Fundament bauen Sie Ihre berufliche Entwicklung auf. Mit unserer Erfahrung, Expertise und Reputation treiben Sie Ihre Karriere voran und wählen den Weg, der Ihrem Profil und Ihren Vorstellungen am besten entspricht.
Zum Beispiel als Consultant bei der Beratung unserer Kunden der pharmazeutischen Industrie oder der Erstellung von Value Dossiers, als Client Service Analyst in der Beantwortung kundenspezifischer Fragestellungen aus Medizintechnik und medizinischer Forschung oder als Sales Manager durch die Akquise von Neukunden. Auch als Clinical Research Associate innerhalb von Research & Development Solutions können Sie im Monitoring von klinischen Studien und der Rekrutierung von Gesundheitszentren den Healthcare Markt voranbringen. Nicht zuletzt leisten unsere Pharma-Außendienstmitarbeiter von Contract Sales & Medical Solutions einen wertvollen Beitrag zur Beratung niedergelassener Ärzte und zur Optimierung der Patientenversorgung im Namen unserer Kooperationspartner.
Konkrete Einblicke in den Arbeitsalltag bei IQVIA Germany geben Ihnen unsere Interviews „Mitarbeiter/innen im Gespräch“.
Werden Sie Teil unserer Community von rund 82,000 Mitarbeitern in über 100 Ländern, die sich dafür einsetzen, das Potenzial von Human Data Science Wirklichkeit werden zu lassen! Kommen Sie an Bord eines führenden, globalen Anbieters von Informationen, innovativen Technologielösungen und Consulting Services für den Gesundheitsmarkt sowie von Dienstleistungen im Bereich der klinischen Auftragsforschung. Unterstützen Sie gemeinsam mit uns die Gesundheitsbranche darin, optimierte Lösungen für ihre Kunden zu finden!
Neben dem Direkteinstieg gibt es bei IQVIA Commercial weitere spannende Möglichkeiten – ob als Trainee, als Student/in im Dualen Studium oder für Werksstudenten/innen.
Auch im Bereich Clinical Research (IQVIA RDS GmbH) haben Sie die attraktive Option, als Trainee oder im Direkteinstieg Ihre Karriere bei IQVIA zu starten.
Unsere verschiedenen Unternehmensbereiche bieten Bewerber/innen vielfältige Chancen für ihren Karrierestart und die weitere berufliche Entwicklung. Detaillierte Informationen finden Sie hier.
Interesse geweckt? Willkommen bei IQVIA!
Bei IQVIA ist Karriere nicht nur ein einfacher Entwicklungsschritt, sondern eine einzigartige Investition in die Zukunft.
(336 words)
- [Adriatic | IQVIA](/content/locations/adriatic/index.html): IQVIA Adriatic Services (238 words)
- [Christina Mack, Ph.D. | IQVIA](/content/about-us/leadership/corporate-leaders/christina-mack/index.html): Christina Mack (191 words)
- [IQVIA Announces Launch of Clinical Trial Financial Suite, a Next-Generation Platform for Integrated Financial Management | IQVIA](/content/newsroom/2025/09/iqvia-announces-launch-of-clinical-trial-financial-suite.html): RESEARCH TRIANGLE PARK, N.C. – September 10, 2025 – IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today announced the launch of its Clinical Trial Financial Suite (CTFS), an AI-enabled platform orchestrating all financial aspects of clinical trials. CTFS is designed to eliminate inefficiencies created by siloed systems and fragmented processes. In contrast to other industry offerings, CTFS unifies budgeting, contracting, forecasting and payment workflows with shared data and end-to-end processes.
The suite’s first module, CTFS Site Payments, brings end-to-end automation to one of the most complex trial processes. By leveraging agentic AI to set up budgets, process invoices and identify anomalies, the module frees up financial teams from repetitive manual tasks to focus their attention more productively.
IQVIA’s technology and operations experts behind CTFS have supported site and participant payments across more than 200 geographies. The solution uses advanced technology to deliver enterprise-grade scalability and security, while deploying AI to drive efficiency and acceleration to the most manual and burdensome processes. Projected customer outcomes include up to 50% reduction in processing time.
“With CTFS, we are building the financial backbone for modern clinical trials — unified, globally scalable and powered by agentic AI,” said Bernd Haas, Senior Vice President, Digital Products & Solutions at IQVIA. “From protocol to payments, we’re connecting and simplifying financial processes into a seamless, transparent experience for sponsors, CROs and study sites alike.”
CTFS Site Payments is slated for general commercial availability in Q1 2026, following a Q4 2025 sandbox release where early adopters will pilot the solution against their business and collaborate on their future needs.
To learn more about CTFS or CTFS Site Payments visit Clinical Trial Financial Suite - IQVIA
About IQVIA
IQVIA (NYSE:IQV) is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA’s portfolio of solutions are powered by IQVIA Connected Intelligence™ to deliver actionable insights and services built on high-quality health data, Healthcare-grade AI®, advanced analytics, the latest technologies and extensive domain expertise. IQVIA is committed to using AI responsibly, with AI-powered capabilities built on best-in-class approaches to privacy, regulatory compliance and patient safety, and delivering AI to the high standards of trust, scalability and precision demanded by the industry. With approximately 90,000 employees in over 100 countries, including experts in healthcare, life sciences, data science, technology and operational excellence, IQVIA is dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide.
IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.
Contacts
Kerri Joseph, IQVIA Investor Relations (kerri.joseph@iqvia.com)
+1.973.541.3558
Alissa Maupin, IQVIA Media Relations (alissa.maupin1@iqvia.com)
+1.919.923.6785
(565 words)
- [Trust first: Why HCP data quality decides how agentic AI scales | IQVIA](/content/blogs/2026/09/trust-first-why-hcp-data-quality-decides-how-agentic-ai-scales.html): As agentic AI takes on more commercial decision-making in life sciences, trust becomes a competitive advantage. Discover why healthcare data quality, verified HCP identity, and identity resolution are critical to scaling AI confidently, and how solutions such as OneKey help create a trusted foundation for personalized engagement and smarter decisions. Read the blog. (1,148 words)
- [IQVIA Wins Multiple Industry Awards for AI and Technology Innovation Across Life Sciences and Healthcare | IQVIA](/content/newsroom/2026/08/iqvia-wins-multiple-industry-awards-for-ai-and-technology-innovation.html): RESEARCH TRIANGLE PARK, N.C. – August 27, 2026 – IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today announced it received recognition this year from multiple independent industry awards programs for its use of AI to help healthcare and life sciences organizations improve decisions, strengthen regulated workflows, protect patient privacy and optimize clinical trial execution.
Healthcare and life sciences organizations are under growing pressure to bring therapies to patients faster, make sense of rapidly expanding volumes of data and adopt AI they can trust. The recognized solutions help address these challenges by combining IQVIA’s proprietary, expert-curated content and data with deep healthcare and life sciences domain knowledge and extensive experience operating in highly regulated environments where compliance, privacy and data governance are critical.
This combination enables customers to turn insight into action with greater speed, precision and accuracy – identifying high-priority patients sooner, accelerating scientific literature reviews, enabling responsible data use at scale, improving regulatory efficiency and strengthening clinical trial supply performance.
In addition to its recently announced AI Breakthrough Award for Best Predictive Modeling Solution of the Year, IQVIA has been recognized this year across multiple global technology awards including American Business Awards® Gold Stevie® for Technical Innovation of the Year – Healthcare Technology – Pharmaceuticals & Biotechnology; MedTech Breakthrough for Best Compliance Solution; American Business Awards® Silver Stevie® for Healthcare Technology Innovation; and another Silver Stevie® for Healthcare & Pharmaceuticals / Product.
Granted by independent organizations that review thousands of submissions annually, the awards provide third-party validation of IQVIA’s ability to deliver meaningful outcomes across R&D, data privacy, regulatory, trial operations and commercial domains.
-
American Business Awards® Gold Stevie® – Technical Innovation of the Year – Healthcare Technology – Pharmaceuticals & Biotechnology: Awarded to IQVIA Literature AI Platform, an agentic system built specifically for scientific literature review that demonstrated 100% recall in search, 93% or higher precision in document screening and more than a 90% reduction in screening workload compared with manual review. The IQVIA Literature AI Platform accelerates the process from search to synthesis while delivering rigorous, traceable outputs aligned with established quality standards.
-
MedTech Breakthrough – Best Compliance Solution: Awarded to IQVIA’s Privacy Analytics Platform, which powers privacy-preserving data use. The technology is deployed within the NHS Federated Data Platform in England, which integrates health data from 55 million patients. The platform has contributed to measurable system impact, including enabling more than 110,000 additional procedures, reducing discharge delays for long-stay patients by 14.9% and supporting more than 90,000 patients in cancer care.
-
American Business Awards® Silver Stevie® – Healthcare Technology Innovation: Awarded to IQVIA SmartSolve® RIM, an AI-enabled Regulatory Information Management platform. It was recognized for helping accelerate global regulatory approvals, strengthen compliance and improve timely access to healthcare products.
-
American Business Awards® Silver Stevie® – Healthcare & Pharmaceuticals / Product: Awarded to the IQVIA Interactive Response Technology (IRT) Supply Automation Value Engine (SAVE) program, which uses real-time analytics and automation to optimize clinical trial drug supply. The program was recognized for reducing instances when trial sites ran out of needed medicines by 76% and cutting drug supply deliveries by 73%.
-
AI Breakthrough Award – Predictive Modeling Solution of the Year: Awarded to IQVIA’s AI-enabled clinical decision support tool, developed in collaboration with Breakthrough T1D. The innovation identifies misdiagnosed and misclassified type 1 diabetes patients. It reduced screening burden by 99.5% – thereby requiring 200 times fewer patient assessments than before. The tool also delivered a ~127x improvement in identifying potential type 1 diabetes patients, with 28% of flagged patients confirmed or suspected to have type 1 diabetes compared with a 0.22% baseline.
Learn more about IQVIA AI.
About IQVIA
IQVIA (NYSE:IQV) is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA’s portfolio of solutions are powered by IQVIA Connected Intelligence™ to deliver actionable insights and services built on high-quality health data, Healthcare-grade AI®, advanced analytics, the latest technologies and extensive domain expertise. IQVIA is committed to using AI responsibly, with AI-powered capabilities built on best-in-class approaches to privacy, regulatory compliance and patient safety, and delivering AI to the high standards of trust, scalability and precision demanded by the industry. With approximately 94,000 employees in over 100 countries, including experts in healthcare, life sciences, data science, technology and operational excellence, IQVIA is dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide.
IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.
Contact:
Kerri Joseph, IQVIA Investor Relations (kerri.joseph@iqvia.com)
+1.973.541.3558
Alissa Maupin, IQVIA Media Relations (alissa.maupin1@iqvia.com)
+1.919.923.6785
(864 words)
- [Unlocking Accelerated Approval Pathways: The Role of Surrogate Endpoints in Drug Development | IQVIA](/content/blogs/2025/05/unlocking-accelerated-approval-pathways-the-role-of-surrogate-endpoints-in-drug-development.html): Explore the role of surrogate endpoints in accelerated approval pathways for drug development. Learn about FDA guidance, traditional vs. accelerated surrogate endpoints, and the case study of Tofersen for ALS using Neurofilament Light Chain (NfL). Understand the challenges and future outlook of surrogate endpoints in groundbreaking drug approvals (510 words)
- [IQVIA™ Institute for Human Data Science Releases Global Oncology Trends 2019 Study: Record Number of Cancer Drugs Launched in 2018 across 17 Indications | IQVIA](/content/newsroom/2019/05/iqvia-institute-for-human-data-science-releases-global-oncology-trends-2019-study-record-number-of-c.html): DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- The IQVIA™ Institute for Human Data Science found in its latest report, Global Oncology Trends 2019: Therapeutics, Clinical Development and Health System Implications, that in 2018 a record-setting 15 new active substance (NAS) oncology treatments with 17 indications, including one tissue-agnostic therapy, launched in the U.S. Those 2018 debuts bring the total number of new oncology therapeutics launched since 2013 to 57 covering 89 approved indications for 23 different tumor types.
In addition to detailing the influx of new oncology drugs within the R&D pipeline and marketplace, the Institute report explores health system barriers hindering the realization of the benefits of those therapies and drug candidates. The report further notes that despite extensive pipeline activity, oncology remains the most challenging area for research and development, facing significant risk of failure and long, costly development.
“Within oncology therapeutic development, the notable successes and failures in recent years have furthered our understanding of the underlying causes of certain cancers, disease progression, and the potential for novel treatments,” said Murray Aitken, IQVIA senior vice president and executive director of the IQVIA Institute for Human Data Science. “However, barriers to adoption of new drugs remain, delaying patient benefit from treatment advances. As treatment options increase, the impact on spending levels has become a focus across most parts of the world – a trend that is expected to continue during the next five years as growth continues.”
Additional highlights of the Global Oncology Trends 2019 report include:
- Innovation in patient therapies: A record of 15 new treatments and one supportive care therapy were launched in 2018, adding a diverse group of therapeutic options with 17 indications across nine tumor types – 11 of the 15 are oral therapies. These 2018 launches increase the total NASs launched over the past five years to 57, which collectively have 89 approved indications for 23 different cancer types. Thirty-one percent of the approved indications during the last five years have been for hematologic cancers - leukemia, lymphoma and multiple myeloma - while lung cancer leads the solid tumors with 12 indications among the 89, followed by breast cancer and melanoma with seven and six indications respectively. The introduction of immunotherapies in 2014, and their subsequent approvals across multiple indications, drove a surge in use by oncologists who treated more than 200,000 patients with immunotherapies in the U.S. in 2018 – double the number of patients treated in 2016.
- Research and development activities: Within the clinical pipeline, activity is most intense for the nearly 450 immunotherapies currently in development, which are identified with more than 60 different mechanisms of action (MOA). At the same time there are more than 100 next-generation biotherapeutics – defined as cell, gene, and nucleotide therapies – in clinical trials focusing on 18 different MOAs. More than 700 companies are driving activity in the oncology pipeline and its late stage development, including 626 emerging biopharma companies almost 500 of which are solely focused on oncology. The largest pharmaceutical companies in the world are also actively pursuing new oncology therapies, with 28 of the top 33 big pharma companies developing anti-cancer molecules.
- Bringing scientific advances to cancer patients: New oncology drugs launched in 2018 took a median of 10.5 years from the time of first patent filing to regulatory approval and launch, an acceleration of more than four years from the 2017 level. Last year, for an oncology therapy with breakthrough status, the average interval from first patent filing to launch was 10.1 years compared to the average for all other therapy areas of 18 years. Despite these trends, access to recently launched oncology medicines by patients living outside large developed countries remains low, with fewer than half of new cancer medicines available to patients beyond nine countries.
- Spending on oncology medicines: Spending on all medicines used in the treatment of patients with cancer worldwide reached nearly $150 billion in 2018 up 12.9 percent for the year and marking the fifth consecutive year of double-digit growth, entirely driven by therapeutic drugs which grew 15.9 percent, as supportive care drugs declined 1.5 percent last year. New brands and protected brand volume contributed nearly all positive growth in major developed markets, resulting in double-digit growth in most countries or regions. Within the United States, spending on cancer drugs has doubled since 2013 and exceeded $56 billion in 2018, with more than $9 billion in growth coming from the use of new PD-1/PD-L1 inhibitors. The average annual cost of new medicines has been trending up for the past two decades, but the median cost dropped $13,000 in 2018 to $149,000, and ranged between $90,000 and more than $300,000.
The full version of the report, including a detailed description of the study methodology, is available at www.IQVIAInstitute.org. The study was produced independently as a public service, without industry or government funding.
About the IQVIA Institute for Human Data Science
The IQVIA Institute for Human Data Science contributes to the advancement of human health globally through timely research, insightful analysis, and scientific expertise applied to granular non-identified patient-level data.
Fulfilling an essential need within healthcare, the Institute delivers objective, relevant insights and research that accelerate understanding and innovation critical to sound decision-making and improved human outcomes. With access to IQVIA’s institutional knowledge, advanced analytics, technology, and unparalleled data, the Institute works in tandem with a broad set of healthcare stakeholders to drive a research agenda focused on Human Data Science, including government agencies, academic institutions, the life sciences industry, and payers. More information about the IQVIA Institute can be found at www.IQVIAInstitute.org.
About IQVIA
IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions, and contract research services to the life sciences industry. Formed through the merger of IMS Health and Quintiles, IQVIA applies Human Data Science — leveraging the analytic rigor and clarity of data science to the ever-expanding scope of human science — to enable companies to reimagine and develop new approaches to clinical development and commercialization, speed innovation and accelerate improvements in healthcare outcomes. Powered by the IQVIA CORE™, IQVIA delivers unique and actionable insights at the intersection of large-scale analytics, transformative technology and extensive domain expertise, as well as execution capabilities. With more than 58,000 employees, IQVIA conducts operations in more than 100 countries.
IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors, and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.
Click here to subscribe to Mobile Alerts for IQVIA.
(756 words)
- [Global Oncology Trends 2025 | IQVIA](/content/library/videos/global-oncology-trends-2025/index.html): The Global Oncology Trends 2025 report explores novel cancer therapies, rising expenditures, and access disparities. It highlights trends in ADCs, radioligand therapies, CAR-T, and spending projections through 2029. (64 words)
- [Data in-action | IQVIA](/content/blogs/2022/06/data-in-action/index.html): Blog Data in-action. Using insight engines as drivers of improved commercial results. (692 words)
- [IQVIA's AI-Enabled Clinical Decision Support Tool Wins 2026 AI Breakthrough Award for Predictive Modeling Solution of the Year | IQVIA](/content/newsroom/2026/08/iqvia-ai-enabled-clinical-decision-support-tool-wins-2026-ai-breakthrough-award.html): RESEARCH TRIANGLE PARK, N.C. – August 20, 2026 – IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today announced that its AI-enabled Clinical Decision Support Tool, developed in collaboration with Breakthrough T1D, has won the 2026 AI Breakthrough Award for Predictive Modeling Solution of the Year.
Powered by IQVIA Healthcare-grade AI®, the tool tackles a long-standing problem in diabetes care: adults with type 1 diabetes (T1D) are often misclassified as having type 2 diabetes (T2D). That mistake delays the right treatment and raises the risk of serious, sometimes life-threatening complications.
Results in practice:
- Cut the screening workload by 99.5%, narrowing reviews from about 60,000 patients down to 300, or roughly 200 times fewer chart reviews.
- Delivered a ~127x increase in diagnostic yield — 28% of flagged patients were confirmed or suspected to have T1D, versus a 0.22% baseline.
- Accelerated the path to the right diagnosis and treatment, helping reduce the risk of complications and improving long-term outcomes.
The Clinical Decision Support Tool was configured in partnership with Breakthrough T1D, the leading global T1D research and advocacy non-profit organization, to enable healthcare providers to close persistent gaps in care, such as delayed diagnosis, missed monitoring and under-treatment.
The AI Breakthrough Awards recognize innovation and performance across the global AI market. This recognition reinforces IQVIA's leadership in applying Healthcare-grade AI® to solve complex clinical challenges and adds to IQVIA's growing portfolio of award-winning AI solutions helping to advance human health.
About IQVIA
IQVIA (NYSE:IQV) is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA’s portfolio of solutions are powered by IQVIA Connected Intelligence™ to deliver actionable insights and services built on high-quality health data, Healthcare-grade AI®, advanced analytics, the latest technologies and extensive domain expertise. IQVIA is committed to using AI responsibly, with AI-powered capabilities built on best-in-class approaches to privacy, regulatory compliance and patient safety, and delivering AI to the high standards of trust, scalability and precision demanded by the industry. With approximately 94,000 employees in over 100 countries, including experts in healthcare, life sciences, data science, technology and operational excellence, IQVIA is dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide.
IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.
Contacts:
Kerri Joseph, IQVIA Investor Relations (kerri.joseph@iqvia.com)
+1.973.541.3558
Alissa Maupin, IQVIA Media Relations (alissa.maupin1@iqvia.com)
+1.919.923.6785
(524 words)
- [Enhancing Patient Safety: A Paradigm Shift Through Early AI Adoption in Pharmacovigilance Workflows | IQVIA](/content/library/white-papers/enhancing-patient-safety-a-paradigm-shift-through-early-ai-adoption-in-pharmacovigilance-workflows.html): In this compelling white paper, IQVIA Vigilance Detect's Marie Flanagan joins fellow industry experts Joann Evangelista and Meredith Kiley of Genentech to explore how early AI adoption in pharmacovigilance workflows can help to advance patient safety. Learn more. (52 words)
- [Healthcare Compliance - United States | IQVIA](/content/locations/united-states/solutions/life-sciences/commercial-solutions/compliance-and-quality/commercial-compliance/healthcare-compliance/index.html): Achieve top-tier regulatory compliance and quality management with IQVIA's Healthcare Compliance Services. (249 words)
- [Medical Specialties and Provider Associations | IQVIA](/content/locations/united-states/solutions/healthcare-solutions/medical-specialties-and-provider-associations/index.html): Medical Specialty Societies can leverage modern registries to improve outcomes, generate high-quality data sets, and benefit from evidence-generation techniques to enhance knowledge and drive healthcare forward. (814 words)
- [Soluzioni - Italia | IQVIA](/content/it-it/locations/italy/solutions/index.html): Studiamo e sviluppiamo soluzioni specifiche per i settori healthcare e life science in Italia partendo dalla nostra expertise a livello internazionale che ci riconosce leader di mercato quali provider di informazioni, tecnologie innovative, servizi di consulenza e di ricerca clinica. (76 words)
- [The everything drugs: from weight loss to whole body medicines | IQVIA](/content/locations/emea/blogs/2025/08/the-everything-drugs-from-weight-loss-to-whole-body-medicines.html): This blog explores comprehensive medicines that address weight loss and overall body health. Learn how these versatile drugs can revolutionize your health and wellness journey. (605 words)
- [OneKey List Finder | IQVIA](/content/locations/united-states/solutions/life-sciences/information-solutions/onekey-reference-data/onekey-list-finder/index.html): Every year OneKey data is audited for quality assurance by the Alliance for Audited Media and is ISO 9001 certified. (371 words)
- [Expanding Business into Ambulatory Surgery Centers | IQVIA](/content/locations/united-states/blogs/2024/03/expanding-business-into-ambulatory-surgery-centers/index.html): Learn what MedTech companies need to know when expanding their business into the Ambulatory Surgery Center space. (844 words)
- [Newsroom | IQVIA](/content/newsroom/index.html): Newsroom (193 words)
- [Therapeutic Areas Driving Clinical Trial Growth | IQVIA](/content/blogs/2026/05/therapeutic-areas-driving-clinical-trial-growth/index.html): Learn how shifts in therapeutic focus, novel modalities, and sponsor profiles are reshaping clinical trial strategy and execution. (1,056 words)
- [media/library/white-papers/medical-science-liaisons-pdf.html](/content/media/library/white-papers/medical-science-liaisons-pdf.html) (740 words)
- [IQVIA Connected Intelligence | Powerful connections for life sciences | IQVIA](/content/about-us/iqvia-connected-intelligence/index.html): Discover how IQVIA Connected Intelligence™ integrates data, expertise, AI, and technology to drive smarter decisions (456 words)
- [Transform Your Medical Devices Contract Management with IQVIA MedTech's 845 Automation | IQVIA](/content/library/case-studies/transform-your-medical-devices-contract-management-with-iqvia-medtech-845-automation.html): Discover how MedTech manufacturers save 450+ hours annually with IQVIA MedTech's 845 Contract Management automation. Download our ROI case study showing $25K-$31K in productivity gains for medical devices companies through automated pricing synchronization and streamlined contract workflows. (303 words)
- [Global Medicine Use Trends 2026 | IQVIA](/content/insights/the-iqvia-institute/reports-and-publications/reports/global-medicine-use-trends-2026/index.html): Analysis of global medicine use and spending through 2030, examining therapy drivers, regional growth, specialty medicines, and evolving health policy dynamics. (970 words)
- [Kundenservice | IQVIA](/content/de-de/locations/germany/solutions/health-system-services/kundenservice/index.html): „Ihr direkter Kontakt für Abrechnung, Datenübermittlung und technische Unterstützung – für Krankenkassen, Leistungserbringer und Partner.“ (77 words)
- [Privacy | IQVIA](/content/about-us/privacy/index.html): Here you can find all of IQVIA's privacy policies. (479 words)
- [Research Support | IQVIA](/content/insights/the-iqvia-institute/research-support/index.html): The IQVIA Institute conducts empirically rigorous, policy-relevant studies to improve the quality and cost-effectiveness of healthcare. (707 words)
- [Solutions | IQVIA](/content/solutions/index.html): Move your business forward and take what's possible in human health further, with offerings powered by IQVIA data, analytics, technology and domain expertise (892 words)
- [A behaviourally informed systematic review of pharmaceutical-led patient support for individuals with cancer | IQVIA](/content/library/scientific-posters/a-behaviourally-informed-systematic-review-of-pharmaceutical-led-patient-support.html): This poster explores the development of a Microsoft 365 Copilot Agent that applies behavioral science frameworks to support faster, more consistent, and evidence-based intervention design in pharmaceutical settings while maintaining expert oversight. (68 words)
- [Compliance Auditing & Monitoring | IQVIA](/content/solutions/safety-regulatory-compliance/commercial-compliance/consulting-and-services/compliance-monitoring/index.html): Leverage compliance program data to empower a proactive approach to risk management. (427 words)
- [Hospitals and Health Systems - United States | IQVIA](/content/locations/united-states/solutions/healthcare-solutions/providers-segment/index.html): Enhance healthcare operations with IQVIA's innovative solutions. Improve patient engagement, reduce costs, and boost efficiencies. Learn more. (367 words)
- [2024年第二季度中国零售药店和医院医药市场回顾与展望 | IQVIA](/content/zh-cn/locations/china/library/brochures/view-point-issue-74/index.html): 2024年第二季度，中国医院医药市场增速趋于平缓。从不同企业类型来看，跨国企业 2024年第二季度销售额 保持正增长，同比增长6.7%；而本土企业相较去年同期有所 下降，季度同比下降2.7%。全国地级市市辖区零售药店市场的销售规 模达到了1056.9 亿 元 人 民 币，较 去 年 同 期 累 计 规 模 下 降 1.2%，消费者购药需求持续低迷。
(30 words)
- [Innovative Funding for Medicines in Latin America | IQVIA](/content/insights/the-iqvia-institute/reports-and-publications/reports/innovative-funding-for-medicines-in-latin-america/index.html): This report outlines a solution framework aimed at reducing the disparity of access to medicines within Latin America relative to other Organisation for Economic Co-operation and Development (OECD) countries (Colombia, Mexico, Brazil, Argentina, Costa Rica) (327 words)
- [Executive Leadership | IQVIA](/content/about-us/leadership/index.html): Meet the IQVIA leadership team that help drive healthcare forward. (140 words)
- [About IQVIA | Accelerating Innovation for a Healthier World | IQVIA](/content/about-us/index.html): Discover how IQVIA leads the way in global healthcare innovation, leveraging data, technology, advanced analytics, and deep expertise to help customers drive healthcare and human health forward. (498 words)
- [IDC MarketScape: Worldwide Life Science R&D Decentralized Clinical Trial Technology Solutions and Consulting Services 2024 Vendor Assessment | IQVIA](/content/library/publications/idc-marketscape-worldwide-life-science-r-and-d-decentralized-clinical-trial-technology-solutions.html): Discover the IDC MarketScape Report on IQVIA's Decentralized Clinical Trial (DCT) Technology Solutions and Consulting Services. This comprehensive report highlights the exceptional strengths of our extensive portfolio, which includes purpose-built DCT technologies such as our DCT platform, eCOA, eConsent, telemedicine, connected devices, and services like labs and home health nursing. Explore IDC's perspective on IQVIA's leadership in strategic flexibile DCT approaches for life sciences companies. Learn how IQVIA is at the forefront of unifying the industry to transform clinical trials. (89 words)
- [Reducing Risk of Stroke for AFib Patients | IQVIA](/content/locations/united-states/library/case-studies/reducing-risk-of-stroke-for-afib-patients/index.html): Learn how IQVIA Healthcare-grade AI identified patients at high risk of stroke, enabled targeted interventions and personalized care plans. (113 words)
- [IQVIA Technologies | IQVIA](/content/es-ar/solutions/technologies/index.html): IQVIA Technologies are purpose-built to orchestrate from molecule to market. Reach milestones faster, always deliver right customer experiences and better ROI. (550 words)
- [U.S. Medicine Use Trends 2026 | IQVIA](/content/library/videos/research-brief-us-medicine-use-trends-2026/index.html): Explore U.S. medicine use, spending, and access trends, including the impact of innovative therapies, rising out-of-pocket costs, and evolving payer dynamics shaping patient access. (76 words)
- [media/iqvia/pdfs/library/fact-sheets/iqvia-ai-clinical-decision-support-tool-fact-sheet-pdf.html](/content/media/iqvia/pdfs/library/fact-sheets/iqvia-ai-clinical-decision-support-tool-fact-sheet-pdf.html) (736 words)
- [IQVIA Safety & Regulatory Compliance Solutions | IQVIA](/content/library/videos/iqvia-integrated-compliance-solutions/index.html): Watch how IQVIA is bringing together technology, services, data and analytics to break down silos and fundamentally change how Quality, Regulatory, Safety and Commercial Compliance work, and work better together (58 words)
- [IQVIA and NVIDIA Collaborate to Transform Healthcare and Life Sciences Through Advanced Agentic AI Solutions | IQVIA](/content/newsroom/2025/01/iqvia-and-nvidia-collaborate-to-transform-healthcare-and-life-sciences.html): RESEARCH TRIANGLE PARK, N.C. – January 13, 2025 – IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights, and healthcare intelligence, today announced a strategic collaboration with NVIDIA to help realize the potential of AI in healthcare and life sciences.
The healthcare and life sciences industries generate vast amounts of data, representing significant potential for AI-powered solutions. This collaboration between IQVIA and NVIDIA will help accelerate IQVIA Healthcare-grade AI™, enabling new levels of agentic automation of complex and time-consuming workflows across the therapeutic life cycle with the precision, scalability, and trust required by IQVIA’s customers. IQVIA has been leading in the responsible use of AI, ensuring that its AI-powered capabilities are grounded in privacy, regulatory compliance, and patient safety. IQVIA Healthcare-grade AI™ represents the company’s commitment to these principles.
The collaboration will combine IQVIA’s unparalleled information assets, analytics, and domain expertise, known as IQVIA Connected Intelligence™, with the NVIDIA AI Foundry service to help transform life science processes from R&D through commercialization. This work is poised to create new efficiencies, enable new operating models, and ultimately improve patient outcomes.
"This represents a significant leap forward in how we apply AI to healthcare and life sciences," said Bhavik Patel, president, Commercial Solutions, IQVIA. "We are excited to combine our industry-leading capabilities and a decade of experience in artificial intelligence with NVIDIA’s advanced AI technologies. We will build new solutions powered by AI agents trained on world-class healthcare information and optimized for life sciences workflows. This collaboration will advance our mission to help our clients accelerate innovation and treatments to market.”
“By integrating NVIDIA AI Foundry platform and services, IQVIA can enhance its Healthcare-grade AI solutions to create custom, domain-specific models and agents for thousands of complex workflows needed in healthcare and life sciences,” said Kimberly Powell, vice president of healthcare, NVIDIA. “AI agents can become digital companions to researchers, doctors and patients, helping unlock enormous productivity and expanding access to care globally.”
IQVIA will work with NVIDIA to develop and optimize AI agents with initial solutions expected to reach market within the calendar year. The collaboration includes access to NVIDIA NIM microservices, NVIDIA NeMo and the NVIDIA DGX Cloud platform, as well as direct support from NVIDIA’s research and engineering teams. Additionally, the collaboration will be deploying the NVIDIA AI Blueprint for multi-modal data extraction to enable access to useful information previously inaccessible to AI models and agents.
About IQVIA
IQVIA (NYSE:IQV) is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA’s portfolio of solutions are powered by IQVIA Connected Intelligence™ to deliver actionable insights and services built on high-quality health data, Healthcare-grade AI™, advanced analytics, the latest technologies and extensive domain expertise. With approximately 88,000 employees in over 100 countries, including experts in healthcare, life sciences, data science, technology and operational excellence, IQVIA is dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide.
IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.
Contacts:
Kerri Joseph, IQVIA Investor Relations (kerri.joseph@iqvia.com)
+1.973.541.3558
Alissa Maupin, IQVIA Media Relations (alissa.maupin1@iqvia.com)
+1.919.923.6785
(673 words)
- [media/iqvia/pdfs/library/fact-sheets/2026/smartsolve-inspection-management-pdf.html](/content/media/iqvia/pdfs/library/fact-sheets/2026/smartsolve-inspection-management-pdf.html) (439 words)
- [Deutschland | IQVIA](/content/de-de/locations/germany/index.html): Wir sind IQVIA, The Human Data Science Company (113 words)
- [People | IQVIA](/content/locations/united-kingdom/esg/people/index.html): At IQVIA, we work to make a positive difference in global healthcare. A focus on People, Public and Planet is central to our approach and helps drive our efforts and contributes to our success. (636 words)
- [Measuring the Impact of Scientific Communications to Drive Launch Excellence | IQVIA](/content/library/white-papers/measuring-the-impact-of-scientific-communications-to-drive-launch-excellence.html): Discover a practical, data-driven framework for Medical Affairs to demonstrate strategic value beyond activity metrics, featuring insights on Scientific Communications, Launch Excellence, Clinical Adoption, Return on Intelligence, and real-world analytics. (188 words)
- [media/iqvia/pdfs/us/fact-sheet/2022/patient-tokenization-pdf.html](/content/media/iqvia/pdfs/us/fact-sheet/2022/patient-tokenization-pdf.html) (344 words)
## About Pages
- [$name | IQVIA](/content/da/contact/index.html): Contact (479 words)
- [$name | IQVIA](/content/ja-jp/contact/index.html): Contact (401 words)
- [$name | IQVIA](/content/nl-nl/contact/index.html): Contact (478 words)
- [$name | IQVIA](/content/es-mx/contact/index.html): Contact (414 words)
- [$name | IQVIA](/content/ru-ru/contact/index.html): Хотели бы узнать больше о возможностях IQVIA? (474 words)
- [$name | IQVIA](/content/fr-ca/contact/index.html): Contact (483 words)
- [Contact Us | IQVIA](/content/contact/index.html): Interested in learning more about how IQVIA can create solutions to help you drive healthcare forward? (134 words)
## Resources
- [Full Page Index](/index.html): Browse all cached pages with rich metadata
- [About This Cache](/about.html): Methodology, technical details, and usage guidelines
- [XML Sitemap](/sitemap.xml): Machine-readable sitemap for crawler discovery
- [Robots.txt](/robots.txt): Crawler directives
- [Agentsite Network](https://agentsite.network/network.html): Public index of Agentsites and their machine-readable resources